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RESUME 
Introduction: L'apoptose est un mécanisme étroitement contrôlé qui répond à des 
besoins particuliers de l'organisme et permet une élimination physiologique des cellules 
excessives ou endommagées. Elle est donc nécessaire au développement et au maintien 
du bon fonctionnement de tout organisme vivant puisqu'elle joue un rôle important dans 
l'embryogenèse, dans les changements morphologiques, dans l'homéostasie cellulaire, 
dans l'atrophie et la réparation des tissus et dans la régression des tumeurs. Cette forme 
de mort cellulaire fait intervenir une famille de sérines protéases connues sous le nom de 
caspases. Leur activation survient après stimulation des cellules par différents facteurs 
comme des signaux physico-chimiques (UV, rayons gamma), la privation en facteurs de 
croissance ou une grande variété des molécules chimiques comme les polluants 
environnementaux et les médicaments anti-cancéreux. Parmi ces derniers on cite 
l'Adriamycine qui est un médicament anti-tumoral efficace, cependant son utilisation 
entraîne malheureusement de sévères altérations du fonctionnement cardiaque. Ceci 
limite par conséquent les doses pouvant être données sans danger aux patients 
cancéreux. D'autre part l'utilisation clinique de ce médicament semble être également 
limitée par la résistance que développent certaines formes de tumeurs à la 
chimiothérapie. Pour surmonter ces deux limites les chercheurs ont essayé de 
développer certaines stratégies thérapeutiques comme l'hyperthermie, visant à 
sensibiliser la tumeur aux faibles concentrations des médicaments. 
Objectifs: La présente étude permettra d'étudier le mécanisme de mort cellulaire induite 
par l'Adriamycine et l'hyperthermie. Les deux principaux piliers de ce projet sont: (1) 
Déterminer si l'Adriamycine ou l'hyperthermie utilisées séparément peuvent déclencher 
l'apoptose chez des cellules tumorales du col utérin humain (HeLa) et chez la même 
lignée exprimant la protéine de résistance aux médicaments MDR (HeLa MRP). (2) 
Déterminer si l'hyperthermie pourrait sensibiliser les cellules à l'action de 
l'Adriamycine. 
Résultats : L'Adriamycine ou l'hyperthermie utilisés séparément ou combiné avait 
comme effet une activation de la caspase initiatrice (9) et de la caspase effectrice (3) 
ainsi qu'un clivage de l'inhibiteur du facteur de fragmentation d'ADN activé par les 
caspases (ICAD). D'un autre coté l'hyperthermie a causé l'accumulation intracellulaire 
de l'Adriamycine, la diminution du potentiel membranaire mitochondriale due à une 
translocation du Bax vers la mitochondrie suivi d'un relarguage du cytochrome c vers 
le cytosol. 
Conclusion: L'hyperthermie seule pourrait induire l'apoptose et pourrait servir comme 
une stratégie utile pour augmenter l'effet pro-apoptotique de l'Adriamycine chez des 
cellules HeLa parentales ou résistantes aux médicaments (HeLa IvIRP). 
Mots clefs: Hyperthermie, Résistance pléiotropique, MRPl, Apoptose, Adriamycine 
ABSTRACT
 
Abstract 
Introduction: Apoptosis is a mechanism of cell death, which provides a physiological 
elimination of excess or damaged cells. It follows a characteristic program of events, 
including activation of the caspase cascade. A wide variety of toxic compounds 
(environmental poilutants, drugs) can induce cell death by apoptosis. Adriamycin is a 
widely used anticancer drug, however, its mechanisms of antitumour activity have been 
a long term matter of debate. In addition, the mechanisms of severe cardiac toxicity, 
which limit the usefulness of the drug, are not weil understood. Multidrug resistance is a 
major obstacle in the successful use of cancer chemotherapy at clinical level. However, 
at present hyperthermia is used as a useful technique to overcome the problem of 
multidrug resistance. Purpose of using hyperthermia, is to increase the anticancer effect 
of Adriarncyin by sensitizing ceil towards drug, at the same time decreasing the toxic 
effect of high dose of Adriamycin. 
Objectives: The present study investigates the mechanism of ceil death induced by 
Adriamycin and hypertherrnia. The two main objectives of this project are: (1) to 
determine whether Adriamycin and hyperthermia alone can trigger apoptosis in human 
cervical adinocarcinoma ceils over expressing MRPI (HeLaMRP) relative to parental 
HeLa cells and (2) to deterrnine whether hyperthermia can enhance the induction of 
apoptosis by Adriamycin. 
Results: Treatment of cells with Adriamycin or hyperthermia alone or combined 
together resulted in activation of caspase-9 and caspase-3 as weil as cleavage of 
inhibitor of caspase-activated DNase (JeAD), which leads to induction of apoptosis. 
Hypertherrnia enhanced intracellular accumulation of Adriamycin, associated to a 
decrease in the mitochondrial membrane potential and translocation of pro-apoptotic 
proteins, Bax and cytochrome c between the cytoplasm and mitochondria of the cell. 
Conclusion: Adriamycin is able to induce apoptosis by the mitochondrial pathway of 
apoptosis in both drug-sensitive and MRP l-overexpressing HeLa cells and hypertherrnia 
alone is enable to induce apoptosis and could be a useful strategy to enhance the 
induction of apoptosis by Adriamycin in both drug-sensitive and MRPI-overexpressing 
HeLa cells. 
Kevwords: Hyperthermia, Multidrug resistance, MRPI, Apoptosis, Adriamycin 
CHAPTER 1 
INTRODUCTION 
1.1 Cancer 
1.1.1 Introduction and history of cancer 
Cancer is a disease, which originates within a single cell. Body cells grow, 
divide and die in an orderly manner until the person becomes an adult. After that, 
cells in most parts of the body divide only to replace depleted or dying cells and to 
repair injury. Cancer develops when there is uncontrolled growth of cells in a part of 
the body. It is a mutation in the cells, which causes them to replicate continuously. 
Ali types of cancer start due to uncontrolled growth of abnormal cells. The discovery 
of "oncogenes", "tumor suppressor genes" and "DNA repair genes" during the 1980s 
and 1990s provided a clearer picture explaining the reason for uncontrollable growth 
of cancer cells. 
The origin of the word "cancer" is credited to the Greek physician 
Hippocrates (460-370 B.C.). He found swollen blood vessels around the area of a 
malignant tumor which reminded him of crab claws leading to the coining of terms 
like karkinos and karkinoma (the Greek name for crab) to depict it. Later on, these 
terms evolved into carcinos or carcinoma. An Egyptian papyrus shows the oldest 
description of human cancer which was wlitten between 3000-1500 BC. Galen, an 
ancient Roman, noted the crab like appearance of cancerous tumors and thought it to 
be caused by an excess of black bile. While the word cancer is frequently used to 
describe this disease, it is important to understand that there are over 200 different 
types of cancer and each has a specifie name, treatment and probability of recovery. 
1.1.2 Development of cancer 
Damage to the DNA is a primary step of development of a tumor cell. 
Generally, the cell is able to repair the damaged DNA. In cancer cells, the damaged 
DNA is not repaired and leads to the formation of a tumor. Tumors can be either 
benign (non-cancerous) or malignant (cancerous). Benign tumors reside in one place 
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in the body and are usually not critical, while for malignant tumors, cells are able to 
invade the tissues around them and spread to other parts of the body. However, there 
are sorne cancers that do not form solid tumors (e.g. leukaemia). 
1.1.3 Canadian cancer statistics 
Each year since 1987, the National Cancer Institute of Canada (NCIC) 
publishes and interprets CUITent statistics about cancer in Canada. These statistics are 
compiled through a collaboration of NCIC, Health Canada Statistics, Canada 
provincial/territorial cancer registries and university-based research. 
According to these statistics, in the year 2004 an estimated 68,300 deaths 
were due to cancer and the number of new cases of cancer was an approximate 
145,500. Breast cancer continued as the most common cancer in women and prostate 
cancer for men, whereas lung cancer remained the other leading cornmon area of 
concem for both men and women. On the basis of CUITent incidence rates, during 
their lifetimes 38 percent of Canadian women and 43 percent of men will develop 
cancer and on the basis of CUITent death rates, 23 percent of women and 28 percent 
of men will die of cancer. According to the age and sex distribution of cancer, people 
who are at least 60 years old are most likely to suffer from cancer. For example, 
among women, 63 percent of new cases and 78 percent of cancer deaths occur 
among those who are at least 60 years old. In addition, it was also predicted that 
cancer would be the leading cause of premature death in Canada in the year of 2004 
(www.cancer.ca). 
1.1.4 Risk factors of cancer 
Understanding the causative factors of cancer could contribute to 
prevention of this disease. There are several risk factors leading to development of 
cancer in humans and most of them are preventable. Tobacco smoke is the single 
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factor known to have caused the highest proportion of cancer and is known to 
cause 30% of ail cancers. Research shows that tobacco consumption is related to 
cancer of the lung, mouth, larynx, esophagus, bladder, kidney and pancreas (Levitz 
et al., 2004; Dol! et al., 1994). Several studies that measured the individual dietary 
fat intake of large groups of women showed that unhealthy diet is one of the main 
causes of breast cancer (Hardy, 2005; van Gils et al., 2005). Environment in the 
work place is also a risk factor for certain fonns of cancer. For instance, workers 
that have direct contact with carcinogenic agents (e.g. arsenic, aluminium, 
asbestos, chromium, cadmium, etc) in the workplace are at risk for developing 
certain fonns of cancer (Wogan et al., 2004; Heath, 1996). Viral infection (e.g. H­
Pylori, HTLV-I, EBV, HBV, HeV and HPV) is also one of the recognized risk 
factors of cancer (Poland and Jacobson, 2004; Evans et al., 1998). Furthennore, 
lack of exercise, excessive alcohol, environmental pol!utants, UV rays and genetic 
susceptibility are also weil known risk factors for cancer. 
1.2 Treatment of cancer 
Cancer treatment varies depending upon the nature of cancer and the phase of 
cancer. Moreover, treatment may vary depending on whether or not the objective of 
treatment is to cure the cancer, to prevent the cancer from dispersion, or to ease the 
symptoms caused by cancer. The three most common ways to treat cancer are 
surgery, radiation therapy and chemotherapy. More recent methods in cancer 
treatment include immunotherapy, gene therapy, enzymotherapy, molecular therapy, 
galvanotherapy (electrochemotherapy), photodynamic therapy, herbaI therapy, 
nutritional therapy, and adjunctive therapies such as hyperthennia, oxygen therapies 
(including ozone), dimethyl sulfoxide (DMSO) therapy, live cell therapy, etc. 
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1.2.1 Surgery 
Surgery is the branch of medical sCIence that treats disease or injury by 
operative procedures. Surgery is useful to diagnose, to determine the stage and to 
treat cancer. There are several types of surgeries, depending on the stage of cancer 
(Fleming, 2001; Pollock and Morton, 2003) and they are often perfonned to 
accomplish more than one of the above mentioned objectives. Preventive 
(prophylactic) surgery is used to remove body tissue that is not malignant but that is 
likely to become malignant such as polyps in colon. Diagnostic surgery helps to 
analyse whether the sample is cancerous or not e.g. biopsy, staging surgery helps 
detennine the extent of disease. Curative surgery is the removal of a tumor when it 
appears to be confined to one area. There are several other classes of surgery that are 
commonly used for cancer treatment such as debulking (cytoreductive) surgery, 
palli ati ve surgery, supportive surgery and restorati ve (reconstructi ve) surgery. 
1.2.2 Radiation therapy 
Radiation therapy is the use of high-energy radiation from X-rays, gamma 
rays, neutrons and other sources to kill cancer cells and shrink tumors. Radiation 
therapy is a highly targeted and effective way to destroy cancer cells and is often used 
after surgery (Perez and Brady, 1998). This reduces the risk of recurrence. Radiation 
therapy is relatively easy to endure and the side effects are restricted to the area being 
treated (Hof and Debus, 2005) and it is also efficient to reduce pain due to the tumor 
(Yorozu et al., 2003). 
1.2.3 Chemotherapy 
Chemotherapy is the use of chemical agents (anti-cancer or cytotoxic drugs) 
which interact with cancer cells to eliminate or control the growth of cancer (Undevia 
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et al., 2005; Trotice, 1997). It is a mainstay in the treatment of malignancies. Cancer 
chemotherapy may consist of single drugs or combinations of drugs and can be 
administered intravenously, injected into a body cavity, or delivered orally (Burke et 
al., 1996). A major advantage of chemotherapy over radiation and surgery is its 
ability to treat widespread or metastatic cancer, rather than physically removing a 
tumor or a part of il. Renee chemotherapy is considered a systemic treatmenl. More 
than half of ail people diagnosed with cancer receive chemotherapy. 
Listed below are several major categories of chemotherapeutic agents based 
on their chemical structures. Alkylating agents such as nitrogen mustards and 
ethylamines are the most commonly used in chemotherapy. Secondly, plant (vinca) 
alkaloids are antitumor agents derived from plants. The best known of this category 
are vincristine and vinblastine (Sui and Fan, 2005). Thirdly, taxanes are groups of 
drugs that include paclitaxel and docetaxel (Earhart, 1999), which are widely used to 
treat advanced ovarian and breast cancers (Khayat et al., 2000; Lamb and Wiseman, 
1998). Finally, antimetabolites, nitrosoureas and anti-tumor antibiotics are among the 
weIl known categories of chemotherapeutic agents. 
Anti-tumor antibiotics are a group of structurally unrelated antimicrobial 
compounds produced by streptomyces species in culture. They are cell cycle non­
specifie. They are distinct from the antibiotics used to treat bacterial infections. 
Rather, these drugs affect the structure and function of nucleic acids by intercalation 
between base pairs and by causing DNA strand fragmentation or DNA cross-linking. 
However, they lack the specificity of the antimicrobial antibiotics and thus produce 
significant toxicity. A number of anti-tumor antibiotics such as Adriamycin, 
dactinomycin, bleomycin and mithramycin are used to treat a variety of cancers. 
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1.3 Adriamycin 
1.3.1 An overview 
Anthracycline antibiotics (Review: Gianni et al., 2003) such as Adriamycin 
are arnong the most important anti-tumor drugs available (Weiss, 1992). They have 
been in clinical practice since the 1960s. Adriamycin is a water soluble anticancer 
agent that was first isolated from Streptomyces peucetius variety casius (Arcamone et 
al., 1969). Doxorubicin is the cornmon trade name of Adriamycin. This drug has been 
used to treat a broad range of malignancies including tumors arising in breast, bile 
ducts, endometrial tissue, liver, soft tissue sarcomas, as weil as various disserninated 
neoplasms, namely leukemia, bone marrow sarcoma, carcinomas of the thyroid and 
bladder and others (Gewirtz, 1999). 
1.3.2 Structure of Adriamycin 
Adriamycin possesses an anthracycline chromophore containing four fused 
rings and a positively charged arnino sugar (Figure 1). Adriamycin shares structural 
similarity with another anthracycline molecule named daunorubicin (DNR). It differs 
only by the presence of a hydroxyl group (-OH) at the 14-position (Taatjes et al., 
1997). Adriamycin consists of a hydroxylated tetracycline quinone attached ta a 
sugar residue via a glycoside bond (Wallace, 2003). As shown in the figure, the 
planar ring system has electronic resonance in the first and third rings with a 
conjugated qui none structure in the second ring. The secondary hydroxyl group on 
the 3rd ring and tertiary group on the 4th ring seem to be key participants in hydrogen 
bonding interactions that stabilize the drug-DNA complex (Gao and Wang, 1991; 
Pohle et al., 1990). 
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Figure 1.1: Schematic representation of Adriamycin and Daunorubucin. 
(Figure adapted from Frederick et al., 1990) 
The qumone portion of the anthracycline ring is lipophilic, however the 
saturated end of the ring system contains abundant hydroxyl groups adjacent to the 
amino sugar, producing a hydrophilic center. Thus the actual molecule is amphoteric 
displaying both acidic and basic properties. The weil conjugated structure of 
Adriamycin is responsible for the red-orange color and fluorescent nature which is a 
useful tool for its chemical, biological and pharmacological studies. 
1.3.3 Mechanisms of action of Adriamycin 
Elucidation of the mechanisms by which anticancer agents induce apoptosis is 
necessary in order to understand the basis of drug resistance as weil as for 
optimization of therapy. The exact mechanism of action of Adriamycin is unknown. 
Several studies suggest that Adriamycin has the propensity to display multiple 
cellular effects, which contribute to its antineoplastic prbperties (Sharples et al., 
2000; Mayers et al., 1998). Adriamycin intercalates into the DNA double helix by 
inserting itself into the strands of genetic material (DNA) inside the cell and binding 
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them together. This prevents the cell fram replicating its genetic material (Halliwell 
and Gutteridge, 1999; Mayers et al., 1998). It also appears to interfere with an 
enzyme called topoisomerase II that is involved in DNA replication (Hurley, 2002; 
Jung and Reszka, 2001; Gewirtz, 1999). Finally, it can also form free radicals which 
are molecules capable of damaging cells (Chandra et al., 2000; Gewirtz, 1999; 
Bachur et al., 1977). Thus, these different actions of Adriamycin impede many 
cellular functions (Sharples et aL, 2000). 
1.3.3.1 Interactions with DNA 
Recent interest in the use of the DNA-Adriamycin complex as an approach to 
improve the therapeutic effectiveness and to reduce toxicity of Adriamycin for cancer 
chemotherapy requires an in-depth understanding of the physicochemical and 
biochemical properties of such complexes. Although the interaction of Adriamycin 
with other cellular targets may play a raie in the selective cytotoxicity of this drug, 
binding to DNA is generally believed to be essential for its activity. The primary 
mode of action of Adriamycin is believed to be its reversible binding to nuclear DNA 
which causes inhibition of both replication and transcription processes (Neidle et aL, 
1997; Zunino et al., 1977, 1975) and subsequently leads to cell death. Numeraus 
biochemical studies including evidence from NMR spectroscopie and X-ray 
crystallographic studies have shown that Adriamycin intercalates into the ~-form of 
the DNA double stranded helix with guanine-cytosine d(CpG) site-specifie 
interactions (Chaires et aL, 1990). These findings were similar to the work of Manfait 
and co-workers (Manfait et al., 1982). They analyzed the Raman and resonance 
Raman spectra of the DNA-Adriamycin complex in aqueous solution. They reported 
that the chromophore of Adriamycin is intercalated in the GC sequences and the 
substituents on the rings give hydrogen-bonding interactions with the DNA base pairs 
above and below the intercalation site. It was also observed that the phenolic groups 
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of the chromophore were involved in the drug-DNA intercalation, in addition to pi-pi, 
hydroxyl and arnino group interactions (Manfait et al., 1982). 
The following events are prerequisite for intercalative interactions between 
Adriamycin and DNA to take place. First, the DNA must undergo a conformational 
transition to form the intercalation site. For this event the DNA base pairs separate 
3.4 Â leading to the formation of a cavity for the incoming Adriamycin-chromophore 
to insert. This is accomplished by localized unwinding of the contiguous base pairs at 
the intercalation site and increasing of the distance between the phosphate groups on 
the sugar phosphate backbone on both strands. This results in reduction of the 
localized charge density and facilitates the release of condensed counter ions such as 
Na+. The next event that occurs involves the transfer of the drug from aqueous 
solution to the intercalation site and finally, it's insertion into the DNA duplex 
(Manning, 1978; Record et al., 1978). The non-covalent interactions between the 
ligand and the base pairs associated with the DNA binding site are driven by several 
forces including hydrophobic effects, reduction of columbic repulsion as a result of 
the polyelectrolyte effect, van der Waals interactions, pi-stacking interactions and 
hydrogen bonding (Record and Spolar, 1990). 
1.3.3.2 Generation of reactive oxygen species 
Adriamycin is also known to be involved in oxidation/reduction reactions. A 
number of NADPH-dependent cellular reductases such as mitochondrial NADPH 
dehydrogenase (Muraoka and Miura, 2003), xanthine dehydrogenase (Yee and 
Pritsos, 1997) and endothelial nitric oxide synthase (Vasquez-Vivar et al., 1997) are 
able to reduce Adriamycin to a semiquinone free radical. Under aerobic conditions, 
the semiquinone is oxidized by molecular oxygen back to the parent compound 
(Adriamycin) and the reaction produces superoxide radical anion (02'-) (Figure 2). 
The formation of O2'- is the beginning of a cascade that generates highly reactive 
oxygen species (ROS) such as hydrogen peroxide (H20 2) and the hydroxyl radical 
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(OH). For instance, superoxide can react with itself leading to the formation of 
hydrogen peroxide (Figure 2) (Minotti et al., 1999; Bounias et al., 1997; Michalska et 
al., 1996). Hydrogen peroxide can react with either the Adriamycin semiquinone free 
radical or it will undergo reductive c1eavage to hydroxyl radicals (OH) (Bates and 
Winterboum, 1982). Ali of these highly reactive free radical species are widely 
invoked as the primary mechanism underlying many of the toxicities observed with 
Adriamycin and related anthraquinones (Tsang et al., 2003; Nakagawa et al., 2002). 
For example, the generation of this semiquinone free radical of Adriamycin has been 
shown to result in the c1eavage of DNA (Lown et al., 1977). Adriamycin is also 
responsible for oxidative modification of nucleic acids, lipids and proteins (Monti et 
al., 1995; Keizer et al., 1990; Piccinini et al., 1990). 
Figure 1.2: The steps from drug reduction to DNA-drug adduct 
formation. This process involves a cascade of reactions starting with drug reduction 
and catalytic production of reactive oxygen species followed by oxidative formation 
of formaldehyde and ending with drug-DNA alkylation mediated by formaldehyde 
(Adapted from Taatjes et al., 1997). 
1.3.3.3 Inhibition of topoisomerase II 
The interaction of Adriamycin with topoisomerase II to form DNA-c1eavable 
complexes also appears to be an eminent mechanism of Adriamycin cytocidal 
activity. Over a decade ago, topoisomerase II was identified to be a primary cellular 
target for many of these DNA binding agents. Topoisomerase II is a nuclear enzyme 
which, in the presence of Adriamycin, causes extensive fragmentation of DNA by 
catalyzing the interconversion of topological isomers of DNA, thereby playing a key 
role in DNA metabolism (Toonen and Hande, 2001; Hengstler et al., 1999). 
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Adriamycin has been shown to exert antineoplastic activity through the formation of 
a temary complex between the ligand, DNA and enzyme. 
1.3.3.4 Metal-ion chelation 
Metal-ion chelation is also one of the cytotoxic characteristics of Adriamycin. 
As previously mentioned, the anthracycline chromophore contains a hydroxyl 
qui none, which is a well-described iron chelating structure. Adriamycin is involved in 
the chelation of metal ions such as Cu+2, Fe+2 and Fe+3 (Kalyanaraman et al., 2002). 
For instance, in the case of iron, Adriamycin tends to form the Adriamycin-Fe-DNA 
complex which catalyses the transfer of electrons from glutathione to oxygen 
resulting in the formation of active oxygen species, which leads to cleavage of DNA. 
1.3.3.5 Membrane effects 
Further action for Adriamycin can be demonstrated at the cell membrane 
level. This drug can bind to cell membrane lipids and affect a variety of functions 
(Solem et al., 1994; Solem and Wallace, 1993). Many studies have highlighted the 
fact that Adriamycin disrupts mitochondrial function by inducing the rnitochondrial 
permeability transition (Ling et al., 1993). This mechanism consists of 
metamorphosis in properties of the inner mitochondrial membrane transforming it 
from a restrictive barrier into passive permeation (Wallace, 2003). In conclusion, 
cytotoxicity and/or antiproliferative activity of Adriamycin may result as a 
consequence of any of the above mentioned mechanisms and/or those not yet 
identified. 
1.3.4 Side effects of Adriamycin 
Regardless of ail the advantages, this drug has various side effects namely: 
diarrhea, facial f1ushing, red coloration of urine, anemia, leucopenia, stomatitis, 
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immunosuppression, mucositis, oesophagitis, nausea and vomiting. However, the 
main limiting factor in its usage as an antitumoral agent is chronic or acute 
cardiotoxicity (Pagnini et al., 2000; Minow et al., 1977). 
Many applications have explained the selective cardiotoxicity of Adriamycin 
(Oison and Mushlin, 1990). However, the pathogenesis of the Adriamycin-induced 
cardiomyopathy is not weil understood. Cardiac toxicity occurs after prolonged 
administration of Adriamycin, eventually leading to congestive heart failure. It has 
been suggested that Adriamycin undergoes redox cycling on mitochondrial complex l 
and liberates highly reactive oxygen free radicals (Doroshow, 1983). These highly 
reactive oxygen species have been widely implicated as a primary cause for 
Adriamycin-induced cardiac toxicity (Xu et al., 2001; Lee et al., 1991). 
1.4 Multidrug resistance 
1.4.1 An overview 
Resistance to multiple chemotherapeutic agents is considered a major cause of 
chemotherapy failure (Linn and Giaccone, 1995). Drug resistance can be classified 
into two categories: 1) intrinsic drug resistance (e.g. renal and prostate cancers) where 
cells already have a relatively resistant phenotype to anticancer agents without drug­
selection; 2) acquired drug resistance (Yoshiyama et al., 2004; Selby, 1984), 
characterised by the attainment of a resistant phenotype after being exposed to 
cytotoxic agents. Acquired drug resistance in persistent tumors is the most critical 
and perilous occurrence for patients treated by chemotherapy. Furtherrnore, once drug 
resistance is developed, cancer cells often acquire cross-resistance to a variety of 
chemically and functionally unrelated compounds. This phenomenon is known as 
multidrug resistance (MDR) (Seiji Naito et al., 1999). 
MDR was first described in 1970 during cell culture by Biedler and Riehm. 
They found cellular resistance to actinomycin D in Chinese hamster cells in vitro 
(Bied1er and Riehm, 1970). Later on, they discovered that this cell !ine also shows 
13 
resistance to vinca alkaloids, epipodophyllotoxines, anthracyclines, dactinomycin and 
taxol. These drugs had different cellular targets and mechanisms of action. It was 
later discovered that increased active drug efflux out of the lvIDR cells resulted in 
reduced accumulation of drugs (Dano, 1973). In 1986, the multidrug resistance gene 
mdr1 was cloned and P-glycoprotein (P-gp) recognized as the first molecule to 
explain the lvIDR phenomenon (Roninson et al., 1986; Chen et al., 1986, Gros et al., 
1986) 
The mechanisms mainly studied for investigation of lvIDR with known 
clinical significance are namely: 1) activation of transmembrane proteins, effluxing 
different chemical substances from the cells; 2) activation of enzymes of the 
glutathione detoxification system; 3) alterations of genes and proteins involved in the 
control of apoptosis (Review: Stavrovskaya, 2000). 
1.4.2 Multidrug resistance proteins 
A variety of ATP binding cassette (ABC) transporters, localized in the cell 
membrane, cause the MDR phenomenon by extruding a variety of chemotherapeutic 
agents from tumor cells. These transporters play a key role in drug availability, 
metabolism and toxicity. The four foremost groups of ABC transporters which are 
involved in lvIDR are namely: the c1assical P-glycoprotein (P-gp) (lvIDRl), the 
multidrug resistance associated proteins (MRP1, MRP2 and probably MRP3, MRP4 
and MRPS) (ABCB 1), the ABCG2 protein and ABC half-transporters. Ali these 
proteins have been known to act as catalysts for ATP-dependent active transportation 
of anticancer agents (Bodo et al., 2003). The following text briefly summarises the 
most important lvIDR related proteins. 
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1.4.2.1 P-glycoprotein 
1.4.2.1.1 An overview 
P-gp (Sakaeda et al., 2004) IS a 170 kDa membrane-bound protein and a 
product of the mdrl gene. It was first characterised in MDR Chinese hamster ovary 
cells by Ling and co-workers (Kartner et a!., 1983; Ling and Thompson, 1974). It has 
been implicated as a primary cause of MDR in tumors (Georges et al., 1990). It is 
generally found in the gut, gonads, kidneys, biliary system, brain and other organs. P­
gp is found not only in cancer cells but also in normal tissue cells, such as 
hepatocytes, renal proximal tubular cells, and epi thelial cells. It serves as an ATP­
dependent efflux pump by actively transporting chemicals and anti-tumor agents out 
of cells thereby reducing their cytosolic concentration. This leads to decreased 
toxicity in cells (Gottesman and Pastan, 1993; Doige et al., 1992). Apart from its drug 
e(f]ux function, P-gp has many proposed physiological functions. Expression of P-gp 
in CD34+ stem cells and specifie peripheral blood subsets raises the possibility that 
P-gp could play a role in haemopoietic development and immune cell functions 
(Lucia et al., 1995; Drach et al., 1992). Specifically, P-gp has been shown to be 
involved in the release of certain cytokines from T lymphocytes (Frank et al., 2001; 
Drach et al., 1998; Raghu et al., 1996). 
1.4.2.1.2 Structure and mechanisms 
P-gp is composed of 1280 amine acids. It has two homologous halves, each 
containing six hydrophobie transmembrane segments and a nucleotide sequence with 
both NH2 and COOH terminaIs of the protein located in the cytoplasm (Gottesman 
and Pastan, 1993). This molecule has two ATP-binding domains indicating that the 
function of P-gp is energy-dependent (Chen et al., 1986). In cancer cells, P-gp is 
associated with the MDR phenotype, mediating resistance to anthracyclines, vinca 
aikaloids, colchicines, epipodophyllotoxins and paclitaxel (Avendano and Menendez, 
2002). Despite numerous studies, it is still difficult to decipher the mechanism by 
which P-gp confers cellular resistance to cytotoxic attack by structurally unrelated 
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drugs. One of the most popular hypotheses proposes that the drug binds to a specifie 
site of P-gp within the lipid bilayer of the cell plasma membrane. Then, by means of 
the energy of ATP hydrolysis, the drug molecule is transported out of the cell. 
Chemotherapeutic drugs were shown to be bound better to the membranes of drug 
resistant cells than to those of drug sensitive cells. 
1.4.2.1.3 Modulators of P-glycoprotein 
P-gp activity is controlled by a variety of endogenous and environmental 
stimuli which induce stress responses including heat shock, irradiation, genotoxic 
stress, inflammation, growth factors and cytotoxic agents (Sukhai, 2000). P-gp 
mediated MDR can be reversed by various chemo sensitizers or reversing agents such 
as Ca2+ channel blockers (e.g. verapamil), immuno-suppressants (e.g. cyclosporine 
A), antiarrhythmic drugs (e.g. quinidine) and many other lipophiJic compounds 
(Gottesman and Pastan, 1993). Ali of these diverse compounds are hydrophobie and 
may bind to the P-gp molecule directly and impede its function in a competitive 
manner (Safa et al., 1989; Naito and Tsuruo, 1989; Nogae et al., 1989). P-gp 
mediated MDR to Adriamycin can be altered by a combination of hyperthennia with 
cyclosporine A and verapamil (Averill and Larrivée, 1998; Averill and Su, 1999). 
This combination is also useful in overcoming melphalan resistance by increasing 
intracellular drug accumulation in multidrug-resistant cells CHRCS cells (CH(R)CS) 
(Larrivée and Averill, 1999). 
1.4.2.2 Multidrug resistance associated protein (MRP1) 
1.4.2.2.1 An overview 
Multidrug resistance protein 1 (MRP1) is a member of the C branch of the 
super family of the ATP-binding cassette (ABCC1) transporter proteins. MRPI was 
originally cloned from an Adriamycin selected MDR human lung cancer cell line 
H69 (Grant et. al., 1994; Cole et al., 1992). MRPI is a human 190 kDa protein, 
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encoded by the mrpl gene, which is located on chromosome 16 (Loe et al., 1996; 
Zaman et al., 1993). The over expression of MRPI is sufficient to confer MDR ta 
structurally diverse natural products and cytotoxic drugs, and to mediate their efflux 
in an ATP dependent manner (Payen and Gao, 2003; Zaman, et al., 1994; Cole et al., 
1992). MRPI is present in almost ail cells of the human body. MRPI is not only 
expressed at the cell membrane, but is also located in the cytoplasm, endoplasmic 
reticulum, or golgi apparatus in sorne cells (e.g. HL/ADR, etc) (Almquist, 1995; 
Marquardt, 1992). It has been detected in tumors with many different cellular origins 
(Leonard, 2003). MRPI is also able to protect normal tissues from the effects of toxic 
substances. The ubiquitous presence of MRPI in many cells, together with the fact 
that this ABC protein can export unconjugated bilirubin (UCB) from the cell, 
suggests that this transporter functions throughout the organism to protect cells 
against accumulation of toxic levels of UCB. 
The clinical cancers exhibiting MRPI expression include hematological 
(Burger et al., 1994a, b; Versantvoort et al., 1994), lung (Savaraj et al., 1994), acute 
lymphoblastic leukemia relapses and chronic myeloid leukemia (Hirose et al., 2003; 
Beck et al., 1994). Moreover, MRPI is found to be over expressed in many non-P-gp 
expressing MDR celilines (Slovak et al., 1993; Cole et al., 1992). 
1.4.2.2.2 Structure of MRPI 
The core structure of MRPI shows similarity to other ABC transporters 
(Figure 3). It has two membrane-spanning domains (MSDs), each followed by a 
nucleotide-binding domain (NBD) (Leslie et al., 2001). 
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MRP1
 
Figure 1.3: Structure of Multidrug Resistance Protein 1 (MRPl): MRPI is thought to 
encode for 17 putative transmembrane domains (TMs). The rectangular bars represent the 
TM domains of MRPl. The nucleotide binding domains are indicated as NBDI and NBD2. 
The extracellular (OUT) and intracellular (IN) sides of the membrane are also indicated. 
(Figure: adapted from Borst et al., 2000) 
A major part of this protein is composed of five transmembrane helices 
(TMDO) and a small cytoplasmic loop of about 80 amino acids (LO) (Bakos et al., 
1998, 1996; Gao et al., 1998, 1996). This intracellular loop (LO) plays a vital role in 
transport activity of the MRPI and :MR.P2 proteins (Femandez et al., 2002). 
However, unlike P-gp, MRPI contains an additional third NH2 proximal membrane­
spanning domain with approximately 280 amino acids (Hipfner et al., 1999). 
1.4.2.2.3 Mechanisms of MRP1 
The MDR phenotype conferred by MRPI is similar, but not identical, to that 
conferred by P-gp. The exact mechanism of MRP 1 mediated transport of cytotoxic 
compounds is not very clear. However, several studies indicate that MRPI can 
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mediate efflux of several conjugated compounds by co-transport with GSH, or in a 
GSH-stimulated fashion by acting as a glutathione-S-conjugate export pump (GS-X 
pump) (Figure 4) (Renes et al., 1999; Loe et al., 1998). MRPI mediated transport is 
ATP dependent, as for P-gp (Muller et al., 1994). Several unconjugated hydrophobie 
drugs such as vinca alkaloids (e.g. vincristine) are transported by MRPI in a 
glutathione dependent manner (Bagrij et al., 2001; Renes et al., 1999; Loe et al., 
1996). The exact mechanism of involvement of GSH in MRPI-mediated transport is 
not clear. One presumption is that glutathione S-transferases (GSTs) catalyze the 
conjugation of GSH to a number of electrophilic xenobiotics and form transportable 
complexes with cationic agents. As a result, the rate of drug detoxification increases 
(Black and Wolf, 1991). 
Glutamyl + Cysteine 
BSO ------i 1y-Glutamyl Cysteine synthetase 
Y-Glu-Cys + Gly!GSH synthetase 
GSH 
+ + GST 
_1+",=/,'::-, , - y X - GS-X 
y x 
Figure 1.4: Interrelation between multidrug resistance-associated protein 
(MRP) and glutathione (GSH). Sorne drugs (X) can be conjugated to OSH by glutathione 
S-transferase (OST) and are then transported out of the cel1 by MRP. Other drugs (Y) are co­
transparted with OSH. In both cases, transportation of the drug depends on the continued 
synthesis of OSH, which can be blocked by buthionine sulfoximine (BSO) (Figure: adapted 
from Barst et al., 2000). 
Finally, MRPI confers resistance to certain antimonial and arsenical 
oxyanions, a function which is not associated with P-gp (Stride et al., 1997; Cole et 
al., 1994). MRPI also appears to be responsible for the preferential drug resistance to 
topoisomerase II inhibitors (Hendrikse et al., 1999). 
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1.4.2.2.4 Substrates of MRPI 
Unlike P-gp, MRPI is a primary active transporter of many conjugated 
organic anions such as sulfate-, glucoronide- and OSH-conjugates. MRPI is also 
the major high-affinity transporter of leukotriene C4, which is an important 
signaling molecule for the migration of dendritic cells from the epidermis to 
lymphatic vessels (Karwatsky et al., 2005; Hipfner et al., 1999; Keppler et al., 
1998). The structural elements that contribute to the affinity of a molecule for 
MRPI are not clearly defined. Several findings suggest that the presence of 
positi vely charged arginine and lysine residues in the MSDs of MRPI (Ito et al., 
2001; Seelig et al., 2000) may facilitate transmembrane transport of charged 
substrates. OSH conjugates have at least two carboxylate residues, which 
contribute to recognition by MRPI. Several other substrates for MRP have been 
identified, such as oxidized OSH disulfide (OSSO) and steroid glucuronides (e.g. 
17b-estradiol 17-(b-D glucuronide) (Homolya et al., 2003; Loe et al., 1996). 
1.4.2.2.5 Modulators of MRPI 
Reversai of MDR offers the hope of increasing the efficacy of conventional 
chemotherapy. Most MDR modulators act by either binding to membrane transport 
proteins (especially P-gp and MRP), thus inhibiting their drug-effluxing activity or by 
indirect mechanisms related to phosphorylation of the transport proteins or expression 
of the mdrl and rnrpl genes. Expression of several MDR-associated genes can be 
affected by cytokines and immunological agents. 
Derivatives of OSH are expected to be good inhibitors of MRPI. Addition of 
OSH to certain unconjugated xenobiotics, results in inhibition of MRPI transport of 
organic anions out of membrane vesicles (Bagrij et al., 2001; Loe et al., 1996). For 
example, transport of LTC4 is inadequately repressed by vincristine or verapamil 
alone, this effect is enhanced more than 20 fold in the presence of OSH. The 
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mechanism by which OSH enhances the inhibitory potency of certain compounds in 
MRPI-mediated conjugated organic anion transport appears to result from increasing 
their affinity for the protein. Sorne dietary flavonoids can also modulate the organic 
anion and OSH transport properties, ATPase activity, and drug resistance-confening 
properties of MRPl. For example, in intact MRPI-overexpressing cells, quercetin 
reduced vincristine resistance from 8.9 to 2.2 fold. It was proposed that camptothecin 
(CPT) could be used for the reversai of the MRPI phenotype at clinically achievable 
concentrations (Chauvier et al., 2002). This study also estab!ished that mifepristone 
was a potent inhibitor of MRPI in vincristine resistant cells (SOC7901/VCR) of 
MDR (Li et al., 2004). A clinical study has shown that the taxane, tRA 98006 is a 
good MDR reversing agent (Brooks et al., 2003). Inhibitors of activity OST of are 
also considered as potent modifiers of MRPI-mediated drug resistance. For example, 
BSO is one of the known inhibitors of y-glutamyl-cysteine synthetase (Figure 4). 
BSO decreases intracellular level of glutathione and thereby overcomes resistance to 
many alkylating agents and reverses resistance to vincristine, rhodamine, doxorubicin 
and daunorubicin in MRPI over expressing cell !ines (Hui-Yun and Kang, 1998; 
Zaman et al., 1994), whereas no effect was observed in MRP-negative parental cell 
!ines. 
1.4.2.3 The canalicular Multispecific Organic anion Transporter: 
cMOAT) (lVIRP2) 
The canalicular membrane of the hepatocyte contains an ATP-dependent 
primary active drug transport system for organic anions, known as the canalicular 
Multispecific Organic Anion Transporter (cMOAT) (Smitherman et al., 2004; Muller 
et al., 1996; Ishikawa, 1992). cMOAT is encoded by a MRPI homologue (Paulusma 
et al., 1996; Ito et al., 1996). It is one of the most extensively studied members of the 
MRP family and is mainly expressed in the liver. It shows 47.6% DNA sequence 
similarity with MRPl. It tends to be rate limiting for the hepatobiliary elimination of 
21 
drugs. cMOAT has similar substrates to MRPl, including drugs conjugated with 
glutathione, glucuronide and sulphate, and natura] product anticancer drugs (e.g. 
anthracyclines, vinca alkaloids, methotrexate, etc). Most of the substrates for the 
cMOAT are bulky organic molecules with two separated negative charges (e.g. 
methotrexate (MTX) derivatives). It has been found that cMOAT related transport is 
associated with bilirubin glucuronide transport, with defects resulting in the Dubin­
Johnson syndrome (Kobayashi et al., 2004). Although its clinical significance in drug 
resistance remains to be determined, expression of cMOAT has been reported in 
human cancers such as breast, leukemia and ovary (Sparreboom et al., 2003). 
At the present time, there are many strategies such as use of pegylated 
chemotherapy (e.g. Pegylated liposomal doxorubicin), organ specific administration, 
intrathecal therapy, hyperoxygen, hyperthermia, etc, which are in use to reverse 
MDR, consequently increasing drug delivery in both cells and tissues (Wartenberg et 
al., 2005; Hau et al., 2004; Dong et al., 1994). Among ail of these approaches, 
hyperthermia is extensively used in the treatment of cancer (Terashima et al., 2004; 
Van der Zee, 2002) and has potential as a MDR reversing technique, which could 
result in chemo sensitization of the tumor cells, denaturation of cell repair enzymes 
and induction of apoptosis (Souslova and Averill-Bates, 2004; Bates and Mackillop, 
1986). 
1.5 Hyperthermia 
1.5.1 An overview 
When cells are heated beyond their nonnal temperature (37°C), they can 
become more sensiti ve to therapeutic agents such as radiation and chemotherapy 
(Schlemmer et al., 2004). The application of heat in a therapeutic setting is referred to 
as hyperthennia. Controlled use of hyperthennia can be used to combat disseminated 
cancers. The extensive amount of biological in vitro and in vivo experimental 
research on hyperthermia during the last decade has established it to be a valuable 
tool in cancer therapy (van der Zee, 2002; Law, 1982; Field and Bleehen, 1979). For 
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over two decades, different forms of hyperthermia have been used in the clinical 
treatment of cancer, thereby proving its effectiveness in combination with both radio­
and chemotherapy (Hehr et al., 2003; Tsuda et al., 2003; Robins et al., 1992). 
1.5.2 History 
The use of heat to treat di sease is a primi ti ve concept. Many ancient cultures, 
including the Egyptians, Greeks, Romans, Chinese, Indians and Japanese have used 
this concept for the treatment of various diseases (Coley, 1891). The field of modern 
hyperthermia was established in the late 19lh century when a number of physicians 
found the curative effects of hot minerai waters (Review: Herman et al., 1982). Upon 
receiving heat treatment, they noted a regression of cancerous tumors for patients 
who had contracted fever inducing disease. In 1887, Dr. Julius Wagner-Jauregg 
began his study of the neurological effects of syphilis. On the basis of data collected 
from numerous reports, he observed a spontaneous remission and apparent cure, after 
a febrile (fever inducing) illness. In 1927, he was honoured by the Nobel Prize for 
this study (Wagner-Jauregg, 1887). Later that decade, Westermark reported the use of 
localized, non-fever produced heat treatments that resulted in the long-term remission 
of inoperable cancer of the cervix (Coley, 1891). Subsequently, sorne studies have 
been carried out highlighting the direct killing effect of heat upon various bacterial 
cultures (Thompson et al., 1936). These results led to clinical trials using heat as a 
treatment for various diseases. 
1.5.3 Types of induced hyperthermia 
1.5.3.1 Extracorporeal whole body hyperthermia (EWBH) 
EWBH offers a means of evenly elevating the temperature by extracorporeal 
circulation throughout the body in a controlled manner for a specified duration of 
time. It was developed to induce controlled, rapid and uniform heating of the body. In 
1976, Leon Parks, a cardiothoracic surgeon, began a series of hyperthermic 
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treatments on patients who had failed ta respond to any conventional treatments 
(Parks et al., 1979). EWBH is also a useful treatment in patients with conventionally 
incurable malignant tumors. Several studies show that induction and maintenance of 
whole body hyperthermia is clinically possible (Lange et al., 1983). 
1.5.3.2 Whole body hyperthermia (WBH) 
Extelllally induced whole body hyperthermia can be used to treat metastatic 
cancers that have proliferated throughout the body (Robins et al., 1992). WBH heats 
the body from the outside in, using sources outside the body. As a result, body tissue is 
subjected to unevenly elevated temperatures. Whole body heating methods include 
saunas, hot air, microwaves and hydrotherapy (immersion in hot water) (Herman et 
al., 1982). Pre-clinical and clinical studies have attributed a number of favorable 
effects to WBH including potentiation of the tumoricidal effects of specific cytotoxic 
agents as weil as stimulation of different features of the immune system (Hildebrandt 
et al., 2004a,b; Hegewisch-Becker et al., 2003). In addition, the combined use of 
WBH and interleukin-2 resulted in enhancement of the anti-tumor response to sarcoma 
45 in rats (Potapnev, 2004). Hence, it can be deduced that WBH could be able to 
contribute to overcoming drug resistance, as weil as to increasing the response to re­
treatment with cisplatin or carboplatin, even after multiple prior chemotherapies 
(Ohno et al., 1991). Several studies have shown excellent response rates with the 
utilization of WBH and chemotherapy for ovarian cancer (Westermann et al., 2001), 
as weil as for other types of cancer, such as sarcoma (Wiedemann et al., 1996; Cronau 
et al., 1992). Irrespective of these benefits, there are a few drawbacks. For instance, 
several clinical observations indicate that diarrhea, nausea and vomiting are commonly 
observed after WBH (Kapp et al., 2000). It was also observed that WBH could cause 
more serious side effects, including cardiac and vascular disorders, although these 
effects are uncommon (van der Zee et al., 2002; Wust et al., 2002; Kapp et al., 2000). 
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1.5.3.3 Regional hyperthermia (RHT) 
RHT is a method used for the treatment of isolated areas of the body, such as 
the liver, pelvis, stomach or limbs (Schlemmer et al., 2004; Petrovich et al., 1989). 
The principle of RHT is to heat intrinsic large tumors. Intraperitoneal hypertherrnia is 
a form of regional hypertherrnia that introduces heated solutions to the abdominal 
cavity via catheters. Magnets and devices that produce high energy such as arrays of 
antennas are placed over the region to be heated. In another approach named 
perlusion, blood is removed, heated and then pumped into the region that is to be 
heated internally. RHT has allowed the use of hyperthermia in conjunction with other 
modalities of antineoplastic therapy (Sticca, 2003). Ir is one of the promising methods 
for the treatment of prostate carcinoma (Tilly et al., 2005; Petrovich et al., 1991). 
Despite advances in this technology of heating, the non-homogeneous character of 
the treatment region can often affect the uniforrnity of the heat dispersion in the 
treated area. This means that is difficult to obtain a uniform regional rise in the 
temperature that is reproducible. 
1.5.3.4 Local hyperthermia (LH) 
LH entails elevating the temperature of superficial or subcutaneous tumors 
while sparing surrounding normal tissue, using either external or interstitial heating 
modalities. The area can be heated externally with high-frequency waves aimed at a 
tumor from a device outside the body. To achieve internai heating, one of several 
types of sterile probes may be used, including thin heated wires, hollow tubes filled 
with warrn water, implanted microwave antennae, radio-frequency electrodes and 
ultrasound. LH has been successfully employed in the treatment of a wide range of 
tumors, particularly solid tumors (Karner et al., 2004). The literature highlights that 
after giving systemic chemotherapy for prostate cancer to patients, LH couId be 
carried out safely and effectively (Sherar et al., 2003). Apart from of aIl these 
25 
benefits, treatments of blood diseases such as leukemia and certain tumor locations 
within the body, such as lung cancer, were difficult using LB. 
1.5.4 Hyperthermia and combination therapy 
Hyperthermia allied with radiotherapy or chemotherapy IS a promlsmg 
method for cancer treatment (Wust et al., 2002; Robins et al., 1992). There is 
considerable medical evidence demonstrating remarkable improvement in response 
rates when hyperthermia is used in combination with radiation therapy or 
chemotherapy (van der Zee et al., 2002). 
1.5.4.1 Hyperthermia and radiation therapy 
The synergistic interactions between heat and radiation have been widely 
studied. The extent of synergism between heat and radiation depends on the 
temperature applied, the time interval between heat and radiation, and the treatment 
sequence (Dahl, 1988). An important mechanism for this interactive therapy is that 
hyperthermia interferes with the repair of radiation-induced DNA damage, probably 
due to an effect on cellular proteins (Kampinga et al., 2001). In both experimental 
animal tumors and clinical treatment of human cancers, hyperthermia has been 
proven to increase the response of malignant tumors to radiation therapy. In vivo 
studies demonstrated that the effect of radiotherapy can be enhanced by a factor of 
1.2 to 5 when combined with hyperthermia (Marino et al., 1992). It has been shown 
that this combination therapy has the following benefits namely: a decrease in the 
radiation dose by 15% to 25%, a decrease in the side effects of X-Ray treatment and 
an increase in the effectiveness of the treatment of superficial and deep-seated tumors 
(Haim and Bicher, 2002). 
The literature confirms that the combination of hyperthermia and radiation, 
with or without chemotherapy, might be a good treatment option for locally advanced 
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inoperable breast cancer (Li et al., 2004). It is also an effective treatment for 
palliation of local symptoms, showing a tendency to achieve local control of large, 
ulcerative advanced breast lesions especially when such treatment is followed by 
salvage surgery (Iemwananonthachai et al., 2003). Moreover, hyperthermia causes an 
increase in tumor blood flow, which results in an improvement in tissue oxygenation, 
thereby provisionally increasing their radio-sensitivity (Rau et al., 2000; Song et al., 
1997). Overall, an important point is that hyperthermia is the most potent radio­
sensitizer known to date. 
1.5.4.2 Hyperthermia and chemotherapy 
Analogous to thermal radio-sensitization, hyperthermia also enhances the 
cytotoxicity of various antineoplastic agents. Several types of interactions of heat 
with chemotherapeutic drugs have been investigated (Urano et al., 1999; Hahn, 1982) 
such as supra additive (alkylating agents, platinum compounds) (Kubota et al., 1993), 
threshold behavior (doxorubicin) and independent effects (fluorouracil, taxanes, vinca 
alkaloids). Hyperthermia increases the cytotoxicity of a wide variety of 
chemotherapeutic agents, including Adriamycin, melphalan, BCNU, bleomycin and 
cisplatin, both in vitro and in vivo (Honess, 1998; Raaphorst et al., 1996; Orlandi et 
al., 1995; Bates and Mackillop, 1990, 1986; Dahl, 1994; Herman et al., 1988; Bates 
et al., 1985). 
Scientific evidence indicates that hyperthermia combined with 
chemotherapeutic drugs is a useful strategy to combat the l'vIDR phenotype mediated 
by P-gp (Larrivée and Averill, 2000, 1999; Averill and Su, 1999; AveriU and 
Larrivée, 1998; Bates and Mackillop, 1990). Melphalan resistance can be modulated 
by hyperthermia combined with ethacrynic acid in a P-gp overexpressing cell line 
(Turcotte and Averill-Bates, 2001). Hyperthermia is also useful in reversai of 
resistance to methotrexate in CHO cells (Herman et al., 1981). Forty two degrees 
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hyperthermia could also be useful as a sensitizer in cisplatin resistant tumor cells 
(Raaphorst et al., 1996). 
The mechanisms by which heat enhances drug toxicity are likely to vary for 
different drugs. Available data suggests that optimal thermal chemo-sensitization 
occurs with synchronous application for most drugs, although there are sorne 
exceptions (e.g. oxacephasporines, cyclophosphamide and ifosfamide) (Urano et al., 
1999; Issels et al., 1990). Recent data suggests that hyperthermia administrated with 
appropriate scheduling caused a modest increase in etoposide-induced apoptosis in 
both drug sensitive parental cell line (e.g. HeLa) and MDR cells with overexpression 
of NIRPI (Souslova and Averill-Bates, 2004). Scheduling was also required for the 
modification of etoposide (VP-16)-induced cell killing by hyperthermia in a 
radioresistant human melanoma (Sk-Mel-3) and a human normal (AG1522) cell line 
(Ng et al., 1996). 
Several phase II studies on hyperthermia in combination with pre- and/or 
postoperative chemotherapy in high-risk sarcomas have demonstrated quite 
impressive 5-year overall survival rates (lssels et al., 2001; Wendtner et al., 2001). 
Simultaneous combination of cisplatin and hyperthermia in cervical cancer, recurring 
following irradiation, resulted in a 50% response rate, which was expected to be 15% 
without hyperthermia (De Wit et al., 1999; Rietbroek et al, 1997). 
1.5.5 Molecular effects of hyperthermia 
Different cell types vary widely in their intrinsic sensitivities to heat. There is 
no consistent discrepancy in heat sensitivity between tumor and normal cells, as weil 
as between MDR cells and their drug sensitive counterparts. For example, 
hyperthennia is equally toxic to both drug sensitive CHü cells (AuxB 1) and their 
multidrug resistant cell line (CHRCs) overexpressing P-gp (Bates and Mackillop, 
1986). Similar results were obtained for human cervical adenocarcinoma cells (HeLa) 
and their MDR counterpart overexpressing MRPI (Souslova and Averill-Bates, 
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2004). However, there appears to be a distinction in sensitivity among rodent and 
human cells. At temperatures between 41°C and 42°C, human tumor cells are less 
heat sensitive than rodent cells, and a potential therapeutic advantage can be achieved 
with prolonged heating at these non-lethal temperatures, though the reason for this 
difference is not known (Annour et al., 1993). The sensitivity of cells to heat also 
varies with phase of the cell cycle, where cells in S phase and mitosis are the most 
heat sensitive (Yuguchi et al., 2002) 
The nature of the critical lesions that lead to cell death following heat 
treatment remains unknown. Several explanations could be that elevated temperature 
results in activation of cell metabolism which causes increased oxidative stress (Lord­
Fontaine and Averill-Bates,1999, 2002) and acidosis of the tumor tissue (Vujaskovie 
et al., 2000; Bicher et al., 1980). Hypertherrnia causes disturbances in the 
microcirculation of cancer tissue (Bogovic et al., 2001) resulting in an inhibition of 
the DNA repair mechanisms (Li et al., 1998; Osman, 1993) and induces apoptosis 
(Sakaguchi et al., 1995). Furtherrnore, it was shown that hyperthennia ean cause a 
disruption of integrin-mediated actin cytoskeleton assembly and, possibly, of other 
integrin-mediated signaling pathways. These effects were shown to be influenced by 
The specifie amplitude and exposure duration, as weil as cell type. For example, 
exposure of mouse epithelial cells to elevated temperatures changed the organization 
of keratin filaments and actin filaments but had no effect on microtubules (Shyy et 
al., 1989). Similar results were observed in 9L cells where heat shock caused collapse 
of microfilaments and intermediate filaments but had only slight effects on 
microtubules (Wang et al., 1998). In contrast, mierotubules were disrupted by heat 
shock in Chinese hamster ovary cells (Lin et al., 1982) and mouse 3T3 cells (Parrish 
et al., 1996). 
Hypertherrnia treatment modulates the activity of cytokines (Katschinski et 
al., 1999; Neville and Sauder, 1988) and increases the antigenicity of tumor cells by 
the production of heat shock proteins (HSP) and activation of natural killer cells 
(Roigas et al., 1998; Multhoff, 1997). Hyperthennia inactivates cellular antioxidant 
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defences against hydrogen peroxide (HzOz) (Lord-Fontaine and Averill-Bates, 2002; 
AveIiIl-Bates and Przybytkowski, 1994). Hyperthennia can act by alteIing the 
transport functions of the plasma membrane. For example, in CHO cells, viscosity of 
the membrane decreased due to increased temperature. This resulted in the elevation 
of the activity of the sodium-potassium pump (Bates et al., 1985). During 
hyperthermia, membrane penneability is changed to several compounds, including 
Adriamycin (Bates and Mackillop, 1987a), polyamines (Gemer et al., 1980) and 
certain ions such as K+ (Bates and Mackillop, 1987b). 
Expression of HSPs is often correlated with the development and loss of 
thennotolerance (Hayashi et al., 2001; Li and Werb, 1982; Landry et al., 1982a, b). 
Expression of other genes modulated by heat requires further investigation such as 
the multiple drug resistance genes (Stein et al., 1999). 
Furthennore, cells exposed to acidic pH during heating have been found to be 
more sensitive to heat treatment (Song et al., 1993). Exposure of cells to heat in a 
nutrient-depIived environment can also sensitize them to heat treatment. This effect 
appears to conelate with changes in the cellular ATP levels (Gerweck, 1988). These 
more specifie temperature-dependent pathways in cells suggest new applications of 
hyperthermia such as heat controlled gene therapy or heat enhanced immunotherapy 
by vaccination. 
1.6 Apoptosis 
1.6.1 Introduction 
Apoptosis is considered to be a distinct fonn of eukaryotic cell death, 
morphologically as weil as biochemically, that occurs under a variety of 
physiological and pathological conditions (Arends and Whyllie, 1991). It is a 
continuous physiologie process of regulated non-inflammatory cell death 
(Hengartner, 2000). Apoptosis was first discovered by Carl Vogt in 1842 (Vogt et al., 
1842). The word "Apoptosis" cornes from the ancient Greek origin, meaning 'falling 
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off of petais from a flower' or 'leaves from a tree in autumn'. The name "Apoptosis" 
was first introduced by John Kerr in 1972. Apoptosis is one of the most acti ve fields 
of biomedical research. The importance of this research was recognized when Dr. 
Horvitz was honored with a Nobel Prize on October i h 2002 for discovering and 
characterizing the genes controlling apoptosis in the nematode Caenorhabditis 
elegans. 
Classically, cell death is believed to occur by one of two mechanisms, 
apoptosis or necrosis (Kerr and Harmon, 1974). These two pathways of cell death 
differ by several criteria. In necrosis, cel! death occurs due to injurious agents leading 
to membrane swelling followed by the leakage of the cell contents resulting in 
inflammation of adjoining tissues as well as wide spread damage (Trump et al., 
1981). Apoptosis is a result of cells committing suicide and has three distinct phases; 
1) shrinkage and fragmentation of cells and their nuclei; 2) condensation of 
chromatin; and 3) extensive degradation of chromosomal DNA (Wyllie and Kerr, 
1980; Wyllie, 1980). 
Apoptosis plays an important role in many biological events including the 
immune system, embryonic development (Barres et al., 1992a,b), metamorphosis 
(Steller et al., 1994; Ishizuya-oka and Shimozawa, 1992), hormone-induced tissue 
atrophy, chemical-induced cell death as well as tissue homeostasis (Arends and 
Whyllie, 1991). An imbalance between cell death and survival may result in 
premature cell death and uncontrolled proliferation (Evan and Vousden, 2001). In 
addition, apoptosis also plays a vital role in the pathogenesis of human disease 
(Fadeel et al., 1999; Thatte and Dahanukar, 1997). For instance, uncontrolled 
apoptosis is implicated in various human diseases such as Alzheimer's, Parkinson's, 
carcinogenesis, intimai hyperplasia, leukernia, lymphoma, etc (Brunner et al., 2003; 
Pritchard and Watson, 1996; Thompson, 1995). 
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1.6.2 Apoptotic pathways 
The three principal mechanisms by which a cell can execute apoptosis are; 1) 
the Intrinsic pathway or mitochondrial pathway where apoptosis occurs by internaI 
signaIs, arising within the cell (Adrain and Martin, 2001); 2) the Extrinsic or death 
receptor pathway, where apoptosis is triggered by external signaIs (Locksley et al., 
2001) and 3) the Endoplasmic reticulum pathway (Rao et al, 2004; Li et al., 2001). 
1.6.2.1 Extrinsic or death receptor pathway . 
Receptor mediated pathway is a major pathway for the induction of apoptosis 
(figure 1.5). The extrinsic pathway begins outside the cell, when conditions in the 
extra-cellular environment determine that a cell should undergo apoptosis. Up to date, 
there are six known members of the death receptors (DR) family including 
Fas/CD95/APO-1 and Tumor Necrosis Factor-ex receptor (TNFex). These two 
members of the death receptor family play a key role in a variety of immunological, 
inflammatory and pathological conditions including initiation of apoptosis (Rudin et 
al., 1997). Both of them belong to the TNF-R family and contain a cytosolic death 
domain (DD). They are located in the plasma membrane of the cell that is ta undergo 
apoptosis and are acti vated by extra cellular ligands. Cytotoxic T lymphocytes 
express Fas ligands that activate cells bearing Fas receptors, thereby inducing 
apoptosis. The Fas receptor is generally found in epithelial tissues, tumors and 
hematopoietic tissues. It is acti vated by binding of Fas ligand (Fas-L) to cell 
membranes, undergoes trimerisation and recruits intracellular molecules known as 
Fas associated death domain (FADD) (Strasser et al., 2000; Ashkenazi et al., 1999). 
The extremity of FADD contains two death effector domains (DEDs) that recruit 
procaspase-8 (Salvesen and Dixit, 1999). The assembled complex of the cytoplasmic 
region of Fas, the adapter protein FADD and procaspase 8 is known as the Death­
Inducing Signaling Complex (DISC). Once caspase-8 is activated, it can activate and 
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cleave downstream effector caspases such as caspase-3 and-7 (Budihardjo et al., 
1999). This results in cleavage of their specific substrates leading to apoptosis. 
Fas-mediated apoptosis a1so inv01ves Bid. In type-II cells the amount of 
DISC produced is low. This results in the activation of small amounts of caspase-8, 
which cleaves the cytosolic substrate Bid. This proteolytically modified Bid leads to 
induction of conformational changes in pro-apoptotic protein BAX that leads to 
permeabilization of the mitochondrial membrane and release of cytochrome c (Eskes 
et al., 2000; Desagher et al., 1999). 
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Figure 1.5: Extrinsic and intrinsic pathways of apoptosis. The death receptor 
pathway starts with ligation of death receptors such as fas/CD95. This leads to the formation 
of the Death-lnducing Signaling Complex (DISe) and activation of caspase 8. Once 
activated, caspase-8 causes the cleavage of caspase 3 that eventually results in DNA 
fragmentation and apoptosis. ln type II cells, the pro-apoptotic protein Bid can act to couple 
the death receptor pathway with the mitochondrial amplification loop. The intrinsic pathway 
can be stimulated by a variety of agents such as irradiation, chemotherapy drugs, reactive 
oxygen species, etc. Mitochondrial damage results in altered membrane permeability leading 
to the release of cytochrome c, that in tum binds to Apaf-1 and procaspase-9 to form a 
complex calIed the apoptosome. Activated caspase-9 then cleaves caspase-3 resulting in 
downstream events involved in cell death (Adapted from Kaufmann and Hengartner, 2001). 
Cancer cells are also susceptible to the tumor necrosis factor receptor (TNF­
R) mediated pathway. The TNF-R can induce apoptosis via different biochemical 
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pathways (Rudin et al., 1997; Maclellan et al., 1997). The most conunonly described 
pathway of TNF-induced apoptosis is regulated by TNF-R associated death-domain 
(TRADD). It commences with the binding of TNF-related apoptosis-inducing ligand 
(TRAIL) to the transmembrane TNF-R and bind to TRADD through its death 
domain. The activated complex of TNF either recruits FADD, leading into signaling 
for apoptosis, or TRAF, leading to anti-apoptotic signaling (Ashkenazi, 2002; 
MacEwan, 2002). TRAF can suppress apoptosis by activating a protein known as 
nuclear factor kB (NF-kB), which acts as an inhibitor of apoptosis protein (JAP) that 
prevents the execution phase of apoptosis (Haimovitz et al., 1994). 
1.6.2.2 Mitochondrial or intrinsic pathway 
A major pathway of apoptosis has been shown to be controlled at the 
mitochondrial level (Figure 1.5) (Susin et al., 1999a; Zamzami et al., 1996). This 
pathway can be activated by a variety of extra and intracellular stresses, including 
oxidative stress, y and UV-radiation, removal of cytokines and treatment with 
different cytotoxic drugs such as Adriamycin, vincristine, vinblastine, etc (Kerr et al., 
1994). These cellular stresses result in the release of cytochrome c from the 
mitochondrial intermembrane to the cytosol, followed by binding of this cytosolic 
cytochrome c to the cofactor apoptotic protease activating factor-l (Apaf-l). This 
binding leads to the formation of the apoptosome (Waterhouse et al., 2002). The 
apoptosome is a -1 tvIDa oligomeric complex, which in the presence of dATPIATP 
self -oligomerizes to form an Apaf-l multimer (Zou et al., 1999) composed of 
cytochrome c, Apaf-l and procaspase-9. This induces the auto activation of initiator 
caspase-9, which subsequently activates other effector caspases (e.g. caspase-3) and 
perpetrates the cell towards death. However, the precise mechanism of cytochrome c 
release is still unclear. Early data suggested that mitochondria played a very 
important role in this process. It was believed that release of cytochrome c was 
dependent on early loss of mitochondrial membrane potential and the opening of the 
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mitochondria penneability pores (Finkel et al., 2001; Desagher et al., 2000). 
Neveltheless, recent data suggest that both events are not essential for apoptotic 
cytochrome c release in ail circumstances (Ly et al., 2003; Waterhouse et al., 2002). 
It has been demonstrated that, upon activation of the intrinsic pathway, a 
range of pro-apoptotic molecules other then cytochrome c are released from 
mitochondria (Figure 5) (Van Loo et al., 2002), such as SmaclDiablo, apoptosis 
inducing factor (AIF), Hsp601l0, endonuclease G (Endo G), etc (Li et al., 2001; Du 
et al., 2000; De laurenzi and Melino 2000; Susin et al., 1999b; Xanthoudakis et al., 
1999; Samali et al., 1999). SmaclDiablo promotes caspase activation by neutralizing 
the inhibitors of apoptosis proteins (IAP's), whereas AIF and Endo G (lia et al., 
2003; Van 100 et al., 2002) lead to a new death pathway that could execute apoptosis­
like cell death in the absence of caspases (Cregan et al., 2002). Endonuclease G is a 
protein found in the inner mitochondrial membrane and like AIF it can also 
translocate from mitochondria to the nucleus during apoptosis and is capable of 
inducing DNA fragmentation independent of caspases (Li et al., 2001). 
1.6.2.2.1 Bcl-2 family of proteins 
The mitochondrial pathway plays a critical role in the regulation of apoptosis 
as major mitochondrial dysfunction is likely to cause cell death. One of the principal 
regulators of the mitochondria-mediated pathway of apoptosis is the family of Bcl-2 
proteins (Cory et al., 2003; Gross et al., 1999; Green and Reed, 1998). Bcl-2 was first 
identified in B cell lymphomas as an oncoprotein coded by a gene affected by 
translocations of chromosome 14 and 18. These proteins can be classified into two 
categories depending on their biological activity namely: Proapoptotic proteins that 
include Bax, Bak, Bik, Bad and Bid and anti-apoptotic proteins such as Bcl-2 and 
Bcl- XdAdams and Cory, 1998; review: Reed, 1997). Presently, at least 15 members 
of the Bcl-2 family are known which can have either a negative or a positive effect on 
the initiation of apoptosis (Shibue and Taniguchi, 2006; review). Despite their widely 
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opposing functions, ail members of the Bcl-2 family have at least one copy of a BH 
motif (BHI-BH4). It was also observed that a subset of the pro-apoptotic members, 
including Bad, Bid and Bim contain only the BH3 domain (Coultas, 2003; Cory et 
al., 2003). These BH domains play an important role in the ability of various family 
members of the Bcl-2 family to interact with each other (Keleker et al., 1997; Cheng 
et al., 1996). They can interact with each other via the BH domains and form either 
death- promoting or death inhibiting hetero-oligomeric complexes. However, the 
significance of these interactions has not been clearly defined (Cheng et al., 1996). 
The relative levels of pro- and anti-apoptotic proteins determine a cell's susceptibility 
to apoptosis (Korsmeyer, 1995). The anti-apoptotic proteins inhibit apoptosis, 
however their site of action is not entirely understood. Proteins such as Bcl-2 can 
control apoptosis induced by various cytotoxic mechanisms and they appear to exert 
their effects by blocking the release of cytochrome c from mitochondria (Kluck et al., 
1997). 
Pro-apoptotic proteins interact with anti-apoptotic proteins and hait their 
inhibition of apoptosis. It was also observed that pro-apoptotic members of the Bcl-2 
family, including Bax, Bak, and Bid, might act directly by destabilizing the outer 
mitochondrial membrane and trigger mitochondrial release of apoptogenic 
cytochrome c and apoptosis-inducing factor into the cytoplasm (Basanez et al., 1999). 
1.6.2.3 Endoplasmic reticulum (ER) pathway 
Recently, the regulation of cell death by endoplasmic reticulum (ER) stress 
has gained much interest (Momoi, 2004; Ferri and Kroemer, 2001). Three major 
apoptotic pathways are involved in ER stress-mediated cell death: 1) Caspase 12­
dependent pathway (Nakagawa et al., 2000); 2) ASK/JNK pathway, which leads to 
induction of cytochrome c release form mitochondria and caspase-9 activation 
(Tournier et al., 2000) and 3) Bap31 and caspase-8 pathway, wherein caspase-8 will 
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be activated by its interaction with Bap31, resulting in cleavage of Bid and 
consequently cytochrome c-mediated cell death (Breckenridge et al., 2002). 
1.6.2.4 Caspases 
The name caspase stands for aspartate-specific cysteinyl proteases. Caspases 
play an essential role in the process of apoptosis. They are involved in both initiation 
and execution of apoptosis (Philchenkov, 2004; Los, 1999; Eamshaw, 1999; 
Thombery, 1998). They can be found in humans ail the way down to insects, 
nematodes and hydra (Los, 2001; Budihardjo et al., 1999; Cikala et al., 1999; 
Eamshaw et al., 1999). To date, at least 14 human caspases with different substrate 
specificity have been identified, although only two-thirds of these have been 
suggested to function in apoptosis (Siegel, 2006; review). Based on their function in 
apoptosis, caspases are categorized into two classes namely: initiator (caspase -8 and 
-9) and effector caspases (caspase -3, -6 and -7). 
Initiator caspases are stimulated by a scaffold-mediated activation mechanism. 
This process involves assembly of a molecular platform in response to death stimuli 
and recruitment of procaspases. This results in the conformational change in the 
initiator procaspases leading to activation of the caspase. Afterwards, mature initiator 
caspases catalyse the processing of effector procaspases to their active enzymes, 
which in tum degrade specific substrates and activate further procaspases 
(Hengartner, 2000). Thus, the initiator caspases act as upstream activators of the 
effector caspases and effector caspases act as executioners by cleaving the proteins 
that actually induce apoptosis in the cell. Initiator caspases such as caspase-8 and -10 
are directly linked to death inducing signaling complexes (DISCs), while caspase-9 is 
recruited to the apoptosome via its caspase activation and recruitment domain 
(CARD). 
The caspases differ significantly in their cleavage specificity and thus have 
different proteins as substrates. A large number of caspase substrates have been 
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identified including the Bcl-2 family, cytoskeletal proteins: gelsoline, fodrin, actin, 
plectrin, cytokeratin; nuc1ear proteins: lamin, survival factor-focal adhesion kinase 
(FAK), p21-activated kinase (PAK), poly ADP-ribose polymerase (PARP), and 
inhibitor of caspase-activated DNase (ICAD) (Virag and Szabo, 2002; Enari et al., 
1998). 
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Figure1.6: A model for CAD-dependent DNA fragmentation during apoptosis. 
When CAO is synthesized on the ribosome, ICAO-L binds to its nascent chain and enhances 
its correct folding. After CAO synthesis is completed, ICAD-L remains complexed with 
CAD as DFF (DNA fragmentation factor) / (CAD/ICAD complex). When apoptotic stimuli 
activate caspase 3, this c1eaves ICAD-L to release active CAD, which degrades chromosomal 
DNA. (Adapted from: Nagata, 2000) 
ICAD is one of the important substrates of caspases (Hengartner, 2000). 
Caspases are responsible for the DNA fragmentation by c1eaving the CAD-ICAD 
complex (Figure 6). CAD is a protein of 343 amino acids, which carries a nuc1ear­
localization signal and produced as a complex with ICAD and exists as an inactive 
form. Treatment with caspase-3 can c1eave this complex leading t~ the release of 
CAD allowing it to enter the nuc1eus and degrade chromosomal DNA (Enari et al., 
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1998). ICAD seems to function as a chaperone for CAD during its synthesis, 
remaining complexed with CAD to inhibit its DNase activity; caspases activated by 
apoptotic stimuli then cleave ICAD, allowing CAD to enter the nucleus and degrade 
chromosomal DNA (Enari et al., 1998). 
1.7 Presentation of Project 
1.7.1 Introduction 
Hyperthermia is used today as a novel technique at the clinical level in cancer 
therapy. The potential of hyperthermia developed due to its ability to increase 
anticancer activity of radiation and of various anti-neoplastic agents and to decrease 
toxic side effects to normal tissue during cancer treatment. This allows targeting of 
chemotherapy with the use of regional heating. Resistance to multiple 
chemotherapeutic agents is considered a major cause of chemotherapy failure. 
Hyperthermia in combined use with chemotherapeutic agents could become a useful 
strategy to combat the multidrug resistance phenotype. Hyperthermia has been used 
increasingly, aimed to overcome drug resistance to chemotherapeutic agents in 
laboratory studies. However interactions between heat and individual drugs are not 
weil understood. The mechanisms by which heat enhances drug toxicity are likely to 
vary for different drugs. Laboratory studies are essential to advance our perception at 
the cellular and molecular levels to ensure that hyperthermia can be combined 
successfully and optimally with chemotherapy in the cancer clinic. 
1.7.2 Objectives of the project 
The two main objecti ves of this project are first, to determine whether, 
hyperthermia can increase the cytotoxicity of the anticancer drug Adriamycin by 
triggering apoptosis in HeLa cells isolated from human cervical adenocarcinoma. The 
second objective is to determine whether hyperthennia can reverse resistance to 
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Adriamycin in HeLa cells with the overexpresslOn of the multidrug resistance 
phenotype MRPl. 
1.7.3 Choice of model 
Two human cell lines from cervical adenocarcinoma were chosen as models 
for this project. The effect of hypertherrnia on Adriamycin cytotoxicity was evaluated 
using cultured human adenocarcinoma cells (HeLa), which are drug sensitive and 
their drug resistant counterpart which, overexpresses multidrug resistance associated 
protein-MRP1 (HeLaMRP cells). HeLaMRP cells were a kind gift from Dr. Philippe 
Gros from McGiIi University, Montreal, QC (Kast and Gros, 1998). The HeLa cel! is 
a weil established in vitro cellular model which is widely used in laboratory research. 
1.7.4 Experimental approach 
The ability of hyperthermia (41°C to 45°C), alone or in combination with 
Adriamycin, to induce apoptosis was evaluated in HeLaMRP versus HeLa cells. 
Cellular uptake of Adriamycin was observed using Adriamycin fluorescence under 
UV illumination using a Zeiss microscope equipped with a mercury lamp. The UV 
illumination induced an orange fluorescence at sites of Adriamycin accumulation 
(Larrivée and Averill, 2000). Induction of apoptosis through the mitochondrial 
pathway was analyzed by subcelluler fractionation of Bax and cytochrome c, by 
measuring the translocation of Bax from the cytosol to rnitochondria followed by the 
release of cytochrome c from mitochondria into the cytosol. The enzymatic activities 
of caspases 3, 8 and 9 were measured by a fluorimetric kinetic assay (Souslova and 
Averill-Bates, 2004). Chromatin condensation in the nucleus of both cell lines was 
evaluated using the fluorochrome Hoechst 33258 (apoptosis) by fluorescence 
microscopy and propidium iodide was used to observe the induction of the necrosis 
(Souslova and Averill-Bates, 2004). Cleavage of ICAD by caspase 3 was also 
observed using Western blotting (Tanel and Averill-Bates, 2005). 
CHAPTER2 
EXPERIMENTAL RESULTS 
2.t·Preface 
This chapter includes a manuscript describing the experimental results of this project 
which I have carried out during the M.Sc program in the laboratory of Dr. Diana 
Averil!. This manuscript will be submitted in the near future to the International 
Journal of Radiation Oncology, Biology and Physics and is entitled "Induction of 
apoptosis by heat shock and Adriamycin in a multidrug resistant human cell line". 
This manuscript was composed by myself, Kamini Barot and was revised by Dr 
Diana Averil!. In this study, I have been engaged in the investigation of cell death 
mechanisms induced by the combined treatment of hyperthermia with Adriamycin 
and its effect on the human cervical adenocarcinoma ceJls with overexpression of 
multidrug resistance associated protein-MRPI. 
2.2-Manuscript 
INDUCTION OF APOPTOSIS BY HYPERTHERMIA AND 
ADRIAMYCIN IN A MULTIDRUG RESISTANT HUMAN CELL 
LINE 
KAMINI BAROT, M.Sc., AND DIANA A. AVERILL-BATES, PH.D.1,2, 
IDépartement de chimie-biochimie and TOXEN, Université du Québec à Montréal, 
CP 8888, Succursale Centre Ville, Montréal, Québec, H3C 3P8, Canada. 
Tel: (514)987-3000(4811); Fax: (514)987-4054; Email: averill.diana@uqam.ca 
1To whom correspondence should be addressed 
2 Formerly Dr. Diana A. Bates. 
Acknowledgements: The authors wish to thank André Tanel, Ahmed Bettaieb, 
Michel Marion and Denis Flipo for valuable technical assistance and Bertand 
Fournier for assistance with statistical analyses. This work was supported by grants 
from the Natural Science and Engineering Research Council of Canada (NSERC) 
(DAB) and the Cancer Research Society (DAB). K. Barot was the beneficiary of the 
Lapointe-Rosendahl and Mario-Plouffe scholarships provided by the Fondation 
UQAM. 
Abbreviations: ADR: Adriamycin; BSA: bovine serum albumin; CAT: catalase; 
CHO: Chinese hamster ovary; DMEM: Dulbecco's modified Eagle's medium; FBS: 
fetal bovine serum; HT: hypertherrnia; HeLa: human cervical adenocarcinoma cells; 
OST: glutathione S-transferase; oPx: glutathione peroxidase; MDR: multidrug 
resistance; MRP1: multidrug resistance-associated protein; SDS-PAOE: sodium 
dodecyl sulphate polyacrylamide gel electrophoresis; SEM: standard error of mean; 
P-gp: P-glycoprotein; PBS: phosphate-buffered saline. 
Running Title: Cell killing by hypertherrnia and Adriamycin in multidrug resistant 
cells 
42 
Abstract 
Introduction: Apoptosis is a mechanism of cell death, which provides a 
physiological elimination of excess or damaged cells. It follows a characteristic 
program of events, including activation of the caspase cascade. A wide variety of 
toxic compounds (environmental pollutants, drugs) can induce cell death by 
apoptosis. Adriamycin is a widely used anticancer drug, however, its mechanisms of 
antitumour activity have been a long term matter of debate. In addition, the 
mechanisms of severe cardiac toxicity, which limit the usefulness of the drug, are not 
weil understood. Multidrug resistance is a major obstacle in the successful use of 
cancer chemotherapy at clinical level. However, at present hyperthermia is used as a 
useful technique to overcome the problem of multidrug resistance. Purpose of using 
hyperthermia, is to increase the anticancer effect of Adriamcyin by sensitizing cell 
towards drug, at the same time decreasing the toxic effect of high dose of 
Adriamycin. 
Objectives: The present study investigates the mechanism of cel! death induced by 
Adriamycin and hyperthennia. The two main objectives of this project are: (1) to 
detennine whether Adriamycin and hyperthennia alone can trigger apoptosis in 
human cervical adinocarcinoma cells over expressing MRPI (HeLaMRP) relative to 
parental HeLa cells and (2) to detennine whether hyperthermia can enhance the 
induction of apoptosis by Adriamycin. 
Results: Treatment of cells with Adriamycin or hyperthennia alone or combined 
together resulted in activation of caspase-9 and caspase-3 as weil as cJeavage of 
inhibitor of caspase-activated DNase (ICAD), which leads to induction of apoptosis. 
Hyperthermia enhanced intracellular accumulation of Adriamycin, associated to a 
decrease in the mitochondrial membrane potential and translocation of pro-apoptotic 
proteins, Bax and cytochrome c between the cytoplasm and mitochondria of the cell. 
Conclusion: Adriamycin is able to induce apoptosis by the mitochondrial pathway of 
apoptosis in both drug-sensitive and MRPI-overexpressing HeLa cells and 
hyperthennia alone is enable to induce apoptosis and could be a useful strategy to 
enhance the induction of apoptosis by Adriamycin in both drug-sensitive and MRPl­
overexpressing HeLa cells. 
Keywords: Hyperthermia, Multidrug resistance, MRPl, Apoptosis, Adriamycin 
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Introduction 
Resistance to chemotherapy treatment is one of the major obstacles to the 
successful treatment of different types of cancer (Linn and Giaccone, 1995). Drug 
resistance can be classified in two categories: 1) intrinsic drug resistance whereby 
tumors already have a resistant phenotype to anticancer agents and 2) acquired drug 
resistance, wherein the resistant phenotype occurs after repeated exposure to 
cytotoxic agents. Furthermore, cancer cells often acquire cross-resistance to a variety 
of chemically and functionally unrelated compounds, a phenomenon known as 
multidrug resistance (MDR). 
A variety of ATP binding cassette (ABC) transmembrane transporters are 
involved in MDR. The most important groups of proteins are the classical P­
glycoprotein (P-gp) and the multidrug resistance associated protein (MRP) (Leonard 
et aL, 2003). These transporters act as ATP-dependent efflux pumps, which actively 
transport a variety of chemicals and antitumour agents out of cells, thereby reducing 
their intraceiJular concentration (Leonard et aL, 2003) 
Multidrug resistance associated protein-l (MRP1) is a human 190 kDa protein, 
encoded by the ABCCI gene, which is located on chromosome 16 (Loe et aL, 1996). 
The c1inical cancers exhibiting high MRPI expression include chronic and acute 
leukemias (Burger et al., 1994) and non-sma\l cell lung carcinomas (Doubre et aL, 
2005). MRPI is a primary active transporter of OSH-, sulphate- and glucuronide­
conjugated organic anions (Jedlitschky et aL, 1996). Several other substrates for MRP 
have been identified, such as glutathione disulfide (OSSO), steroid glucuronides (e.g. 
17b-estradioI17-(b-D glucuronide) (Leo et aL, 1996) and cysteine leukotriene (LTC4) 
(Hipfner et aL, 1999). The exact mechanism of MRPI-mediated transport of 
cytotoxic compounds is not clear. However, several studies indicate that MRPI can 
mediate efflux of several conjugated compounds by co-transport with glutathione 
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(GSH) or in a GSH-stimulated fashion by acting as a glutathione-S-conjugate export 
pump (GS-X pump) (Renes et al., 1999). 
Overexpression of MRPI is responsible for cellular resistance to several 
anticancer drugs, including Adriamycin, vinca alkaloids and epipodophyllotoxins 
(Hipfner et al., 1999). Adriamycin is a widely used anticancer agent, belonging to the 
family of anthracycline antibiotics (Gerwitz, 1999). The mechanism of action of 
Adriamycin is not entirely clear. However, it is known to intercalate into DNA, 
causes the generation of free radicals, induces lipid peroxidation, initiates DNA 
damage as a result of topoisomerase II inhibition, causes direct membrane effects and 
induces apoptosis. 
Apoptosis is a mechanism that organisms have evolved to eliminate excess 
cells, or cells that are damaged, neoplastic, or infected with viruses (Hengartner, 
2000). The principal mechanisms by which a cell can execute apoptosis are the 
mitochondrial, the death receptor and the endoplasmic reticulum pathways (Rao et 
al., 2004). Deregulation of apoptosis can lead to development of a variety of cancers 
(Pri tchard and Watson, 1996). 
ReversaI of MDR offers the hope of increasing the efficacy of conventional 
chemotherapy. At the present time, several strategies are in use to reverse MDR, such 
as inhibitors of drug efflux pumps such as verapamil and cyclosporine A (Baird and 
Kaye, 2003), pegylated chemotherapy (Hau et aL, 2004) and organ specific drug 
administration (Dong et aL, 1994). These approaches generally increase drug delivery 
in cells and tissues. It is important to deveJop new approaches to reverse MDR. 
Hyperthermia is widely used in the clinical treatment of cancer (Van der Zee, 
2002), particularly in combination with chemotherapy and radiotherapy (Hehr et al., 
2003). A wide range of in vitro and in vivo studies demonstrated that hyperthennia 
increases the cytotoxici ty of a wide variety of chemotherapeutic agents, including 
Adriamycin, melphalan, BCNU, bleomycin and cisplatin (Raaphorst et al., 1996; 
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Bates and Mackillop, 1990, 1986; Honess, 1988; Bates et al., 1987). Hyperthermia 
could also be a useful strategy to overcome drug resistance. MDR cells 
overexpressing P-gp (Bates and Mackillop, 1986) or MRP-l (Souslova and Averill­
Bates, 2004) were sensitive to heat killing. To further support the usefulness of 
hyperthermia, drug-induced cell death by teniposide and topotecan (Hermisson and 
Weller, 2000), cispl atin (Raaphorst et al., 1996) and methotrexate (Herman et al., 
1981) was increased by hyperthermia in cells exhibiting primary drug resistance. In 
NIDR cells, hyperthermia enhanced drug sensitivity of melphalan (Bates and 
Mackillop, 1990) and liposomal Adriamycin (Gaber, 2002). Furthermore, 
hyperthermia combined with P-glycoprotein modulators, such as verapamil, 
cyclosporin A or PSC833, increased the effectiveness of drugs such as Adriamycin, 
melphalan and vinblastine, in the elimination of MDR cells (Averill and Su, 1999; 
Averill and Larrivée, 1998; Dumontet et al., 1998, Liu et al., 2001). 
The present study explores the possibility of reversing resistance to Adriamycin 
using hyperthermia in human cervical adenocarcinoma (HeLa) cells overexpressing 
MRPI (HeLaMRP). The objective of the study is to determine whether heat can 
increase the induction of apoptosis by Adriamycin in HeLa cells and in their MDR 
mutant overexpressing MRPI. Apoptotic events are evaluated at the level of 
mitochondria, caspase activation and cleavage of caspase substrates. 
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Materials and Methods
 
Tissue culture
 
HeLa (ATCC no. CCL-2) cells were grown in monolayer in Dulbecco's 
modified Eagle medium (DMEM) (Gibco Canada, Burlington, ON) which contains 
high glucose with L-glutamine (2mM) and pyridoxine hydrochloride. This medium 
was supplemented with 10% fetal bovine serum (FBS) (Gibco Canada) containing 
penicillin (50 units/ml) and streptomycin (50Jlglml) (Flow Laboratories, Mississauga, 
ON), sodium pyruvate (l.OmM), sodium bicarbonate (1.5g1L) and nonessential amino 
acids (O.lmM) (Souslova and Averill-Bates, 2004). The multidrug resistant HeLa­
MRP cell line was a kind gift from Dr. Philippe Gros, McGill University, Montreal, 
QC (Kast and Gros, 1998). These cells are resistant ta Adriamycin, etoposide, 
actinomycin D and vincristine. The culture medium for HeLa-MRP ceUs contained 
etoposide (VP-16) (250nglml), which was removed for the final passage prior to 
experiments. Cell Iines were maintained in tissue culture flasks (Sarstedt, Saint­
Laurent, QC) in a humidified atmosphere of 5% CO2 at 37°C using a water jacketed 
incubator. Cells were grown to confluence and the culture medium was changed 24h 
prior to experiments. Cells were harvested using trypsin (0.5mglml)-EDTA 
(0.2mglml) (Gibco Canada) and washed again by centrifugation (lOOOg, 3min). 
Adriamycin uptake 
Freshly harvested HeLa and HeLaMRP cell suspensions were plated onto sterile 
coverslips in culture dishes at a concentration of 0.5xlü6 cells per dish and incubated 
ovemight at 37°C in an atmosphere containing 5% CO2. Cells were incubated for Ih 
with Adriamycin (l0 and 20JlI), either alone at 37°C or combined with 42°C heat 
shock. Then, coverslips containing cells were washed twice with ice-cold PBS, 
inverted onto slides and viewed for fluorescence under UV illumination using a Zeiss 
microscope equipped with a mercury lamp (model Il\1, Carl Zeiss Canada Ltd., St. 
Laurent, QC). The UV illumination induced an orange-red fluorescence at sites of 
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Adriamycin accumulation (Larrivée and Averi Il , 2000). Quantification of 
fluorescence intensity in cells was carried out using Northem Eclipse Software 
(Empix Imaging, Mississauga, ON). At least 100 cells were counted per sample. 
Heat and drug treatment 
For the effect of heat al one, cells were incubated for 1 or 2h at temperatures 
ranging from 37 to 45°C, in temperature-controlled water baths (0±.0.02°C) (Haake 
D8, Fisher Scientific, Montreal, QC). For the effect of drug alone, cells were 
incubated for either 15h (caspase 9, Bax and cytochrome c) or for 18h (caspase 3, 
rCAD and Hoechst) at 37°C in an incubator containing 5% COz. For the combined 
effect of heat and drug, cells were incubated at 42°C (iO.1°C) during the 1st hour of 
the 15h or 18h drug treatments. 
Subcellular fractionation and Western blot analysis of Bax, cytochrome c 
and ICAD 
Following treatment with Adriamycin alone or combined with 42°C heat shock, 
cells were harvested, homogenized using a dounce homogenizer (50 strokes/sample) 
and then lysed in 500fLI of lysis buffer (Samali et aL, 1999) containing 100mM 
sucrose, 1mM EGTA, 20mM 3-N-morpholino-propanesulfonic acid (MOPS), 0.1 mM 
dithiothreitol (DTT) , 5% freshly added percoll, 0.01% digitonin, 1mM phenyl­
methyl-sulfonyl fluoride (PMSF) and 100fLl/lOml of cocktail of protease inhibitors 
(AEBSF, Aprotinin, Bestatin, E-64, Leupeptin and Pepstatin A) (Sigma-Aldrich, 
rnc., Saint-Louis, MO), pH 7.4. Debris, unbroken cells and nuclei were removed by 
centrifugation (lO,OOOg, lOmin), to provide whole cell lysates. For subcellular 
fractionation, supematants were then centrifuged (15,000g, 15min) to separate 
mitochondria. Supematants were then centrifuged (lOO,OOOg, Ih) to separate 
cytosolic and nucleosomal fractions (Jurkiewicz et aL, 2004). Mitochondrial fractions 
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were resuspended in lysis buffer (300mM sucrose, ImM EGTA, 20mM MOPS, 
O.1mM DIT, 100ul/l0ml of cocktail of protease inhibitors, pH 7.4). For the 
immunodetection of ICAD, whole celllysates were used. 
Protein concentrations were determined according to Bradford (1976). Proteins 
(30,ug) from mitochondrial and cytosolic fractions, or whole cell lysates, were 
solubilised in sample buffer (Laemmli, 1970), heated for 5 min at 100°C and 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (15% gel for 
Bax, cytochrome c; 10% gel for ICAD) using a constant voltage of 125V. Cellular 
proteins were transferred to polyvinyl difluoride (PVDF) membranes using a 
Milliblot Graphite Electroblotter l apparatus (Millipore, Bedford, MA). The transfer 
buffer contained 96mM glycine, 10mM Tris and 10% methanol. The transfer was 
carried out for 1.5 h at constant amperage of 80mA/gel. Hydrophobie or non-specifie 
sites were blocked using skim milk in Tris-buffered saline (50mM Tris and 150mM 
Nacl) containing 0.1% Tween 20 (TBS-T) for Ih at room temp or ovemight at 4°C. 
Membranes were washed and probed with mouse anti-cytochrome c monoclonal 
antibody (1: 1000) (BD Biosciences, Mississauga, ON), rabbit polyclonal anti-Bax 
antibody (1:2000) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or polyclonal 
rabbit anti-ICAD antibody (1:1000) (Santa Cruz Biotechnology Inc.) for Ih at room 
temperature or ovemight at 4°C. Membranes were washed and then incubated for Ih 
with horseradish peroxidase (HRP)-conjugated rat Mab-anti-rabbit IgG (1: 1000) 
(Biosource, Camarillo, CA). Membranes were incubated In ECL-Plus 
chemiluminescence reagent (Amersham Bioscience Corp., Piscataway, NJ) for 1 min 
and films (Fuji medical X-ray film, Düsserldorf, Germany) were scanned with a 
Laser Scanning Densitometer (Alpha Innotech Corp., San Leandro, CA). Expression 
of Bax, cytochrome c and ICAD was quantified using IPGEL software. Purity of 
cytoplasmic and mitochondrial fractions was verified using antibodies to GSTnl 
(Calbiochem, La Jolla, CA) and cytochrome c oxidase (Molecular Probes, Eugene, 
OR), respectively (data not shown). 
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Enzymatic assays of caspase-9 and ·3 activities 
Following incubation with Adriamycin and or heat, cells (lxlOG) were 
harvested, resuspended in PBS-BSA 1% containing lOmM glucose and then 
centrifuged in a microfuge (3min, 4000rpm). Cells were resuspended in 50fLi of 
reaction buffer (20 mM piperazine-N,N'-bis (2-ethanesulfonic acid) (PIPES), 100mM 
NaCI, lOmM DIT, 1mM EDTA and 0.1% 3-[(3-cholamido-propyl)­
dimethylammonio]-2-hydroxy-l-propanesulfonic acid (CHAPS), 10% sucrose, pH 
7.2) (Stennicke and Salvesen, 1997). A 25fLi aliquot of this solution was seeded into 
96-well plates and the cells were then lysed by freezing at -20°C for 15min. Fifty fLI 
of reaction buffer were added to each sample and then specific caspase substrates 
(25fLl) (200fLM) (Calbiochem, San Diego, CA) were added; Ac-Leu-Glu-His-Asp-7­
amino-4-trifluoromethylcoumarin for caspase-9 and Ac-Asp-Glu-Val-Asp-amino-4­
methylcoumarin for caspase-3. The kinetic reaction for caspase activity was followed 
for 30 min, at respective excitation and emission wavelengths of 400nm and 505nm 
for caspase-9 and 380nm and 460nm for caspase-3, using a spectrofluorimeter 
(Spectra Max Gemini, Molecular Devices, Sunnyvale, CA). 
Morphological analysis of cell death 
Following treatment with Adriamycin and/or 42°C hypel1hennia, 50fLg/ml of 
Hoechst 33258 (Sigma Chemical Co.) was added for 15min at 37°C, in order to stain 
apoptotic ceUs (blue-green fluorescence). Hoechst 33258 binds to condensed 
chromatin in the nucleus of apoptotic ceUs. Propidium iodide (Sigma Chemical Co.) 
(50fLglm1) was subsequently added to visualise necrotic ceUs (red fluorescence). 
Apoptotic and necrotic ceUs were observed by fluorescence microscopy (model lM, 
Carl Zeiss Canada Ltd, St. Laurent, QC) and photographs were taken using a Sony 
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digital 3CCD Color Video Camera and analysed using Northem Eclipse software 
(Empix Irnaging, Mississauga, Ontario). At least 300 cells were counted per sample. 
Statistics 
Data are presented as means ± standard error of the mean (SEM) from at least 3 
independent experiments performed with multiple estimations per point. For 
statistical analysis of data for cytochrome c, Bax, JC-I, drug accumulation and 
caspases, average values were compared to a control value. The control value was 
subtracted from each observation and a bilateral t-test was performed to see if the 
average value is null. A Bonferroni-Holm (sequentially rejective method) adjustment 
was performed to control for the family wise error (FWE) rate at 5%. A one way 
analysis of variance (ANOVA) and closed testing procedures adjustment using the 
macro Simlntervals (Westfall et al., 1999) were used for multiple comparisons 
between averages, except for ICAD and Hoechst tests, where the Dunnett bilateral 
test was performed for adjustment of P-values. Software used was JMP Statistical 
Discovery 4.0 (SAS Institute Inc., Cary, NC). Differences were considered 
statistically significant at P < 0.05. 
51 
Results 
Adriamycin accumulation in parental and MDR HeLa cells: Effect of 
hyperthermia. The MDR phenotype is often associated with decreased drug 
accumulation. We determined whether this was the case for resistance to Adriamycin 
in HeLaMRP cells. Intense fluorescence was clearly distinguishable in the parental 
HeLa cells, following a 60 min exposure to Adriamycin (10 and 20 /lM) at 37°C (Fig. 
lA, lC). In contrast, MDR cells displayed only faint Adriamycin fluorescence (Fig. 
lE, lH). Adriamycin accumulation was significantly lower in HeLaMRP cells 
compared to HeLa cells at 3rC (Fig. II). Hyperthermia (42°C) caused an increase in 
the intensity of Adriamycin fluorescence in HeLa parental cells (Fig. lB, ID, II), but 
demonstrated little effect in HeLaMRP cells (Fig. IF, lH, II). 
Adriamycin and hyperthermia, alone or combined, induce the 
translocation of Bax and cytochrome c. An important molecular event in apoptosis 
is translocation of pro-apoptotic proteins such as Bax from the cytoplasm to 
mitochondria, thus interfering with anti-apoptotic functions of proteins like Bcl-2. As 
a consequence, release of pro-apoptotic proteins such as cytochrome c from 
mitochondria will be promoted. Adriamycin induced the translocation of Bax from 
the cytoplasm to mitochondria in HeLa (Fig. 2A, 2C, 2E, 20) and HeLaMRP (Fig. 
2B, 2D, 2F, 2H) cells, at 37°C. Bax expression decreased in the cytosolic fraction 
(Fig. 2A- 2D) with a corresponding increase in the mitochondrial fraction (Fig. 2E­
2H). These changes were dependent on Adriamycin concentration and occurred at 
higher concentrations (2-10 IlM) in MDR cells (Fig. 2D, 2H), compared to parental 
cells (0.5-2 IlM) (Fig. 2C, 20). Two IlM Adriamycin induced more pronounced 
changes in Bax expression in HeLa cells compared to MDR cells. Hyperthermia 
(42°C) alone induced translocation of Bax from the cytosol to mitochondria to a 
similar extent in both cell lines. Hyperthermia increased the effect of Adriamycin on 
Bax expression in cytosolic and mitochondrial fractions in both cell lines. Levels of 
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cytochrome c in the cytoplasmic fraction increased in both cell lines with increasing 
Adriamycin concentration (O.5-2jlM for HeLa, 2-lOjlM for HeLaMRP cells) at 37°C 
(Fig. 3A-3D). There was a corresponding decrease in cytochrome c expression in 
mitochondrial fractions (Fig. 3E-3H). Hyperthermia alone caused release of 
cytochrome c from mitochondria into the cytosol to a similar extent in both cell!ines. 
Adriamycin-induced liberation of cytochrome c from mitochondria was increased by 
42°C hyperthermia in both HeLa (Fig. 3C, 30) and MDR (Fig. 3D, 3H) cells. 
Caspase activation by hyperthermia and/or Adriamycin. A major 
downstream event from cytochrome c release in mitochondria-mediated cell death is 
activation of the initiator caspase 9. Hyperthermia induced activation of caspase 9 
relative to unheated control cel1s at 37°C (Fig. 4A). Activation of caspase 9 occurred 
at 41-42°C in HeLa cel1s and at 41°C in HeLaMRP cells (Fig 4A). Caspase 9 activity 
decreased below control levels at 45°C for both cell lines (Fig.4A). Adriamycin 
caused an increase in the activity of caspase 9 in HeLa (Fig. 4B) and HeLaMRP (Fig. 
4C) cells at 37°C. Caspase 9 activation occurred at higher drug concentrations (2­
lOjlM) in MDR cells, compared to parental cel1s (O.5-2jlM). Hyperthermia caused an 
increase in activation of caspase 9 by Adriamycin in both ceillines (Fig. 4B, 4C). 
Caspase 3 is a downstream target of cleavage by caspase 9. Hyperthermia 
induced the activation of caspase 3 (Fig. 5A) relative to unheated control cells at 
37°C. Activation of caspase 3 was observed at 41-42°C in HeLa and HeLaMRP cells 
(Fig. 5A). The activity of caspase 3 decreased below control levels at 45°C. 
Adriamycin (O-2jlM for HeLa, O-lOjlM for HeLaMRP cells) caused a concentration 
dependent increase in the activity of caspase 3 in HeLa and HeLaMRP cells at 37°C 
(Fig. 5B, 5C). Hyperthermia (42°C) caused an increase in activation of caspase 3 by 
Adriamycin in both cell !ines (Fig. 5B, 5C). 
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Cleavage of caspase 3 substrate ICAD by Adriamycin and/or 
hyperthermia. 1CAD is a weil established cleavage target of caspase 3. Adriamycin 
caused a concentration dependent decrease in the expression of 1CAD, which 
indicates cleavage of 1CAD, in HeLa (Fig. 6A, 6C) and HeLaMRP cells (Fig. 6B, 
6D). Hypertherrnia (42°C) alone caused cleavage of 1CAD and increased that caused 
by Adriamycin. 
Morphological analysis of apoptosis induced by Adriamycin alone or 
combined with hyperthermia. One of the later events in the apoptotic cascade is 
chromatin condensation in the nucleus. This event can be triggered by activation of 
CAD, resulting from 1CAD cleavage by caspases (Nicholson, 1999). Figure 7 
illustrates induction of apoptosis (chromatin condensation) and necrosis by 
Adriamycin, whether alone or combined with 42°C hypertherrnia. The number of 
apoptotic cel1s with condensation of chromatin increased steadily with Adriamycin 
concentration after 18h at 37°C for HeLa (Fig. 7A-7D, 71) and HeLaMRP cells (Fig. 
8E-8H, 8J). The HeLaMRP cel1s (Fig. 7J) were more resistant to induction of 
apoptosis by Adriamycin than HeLa cells (Fig. 71) (note that higher Adriamycin 
concentrations were used for HeLaMRP cells). Hypertherrnia (42°C) alone caused 
chromatin condensation in HeLa cells. Hyperthermia caused a significant increase in 
Adriamycin-induced apoptosis in HeLa ce1ls (Fig. 71), but a low effect was observed 
in MDR cells (Fig. 7J). Adriamycin caused a significant increase in the number of 
necrotic cells in HeLa cells at 37°C and 42°C at higher doses (2,uM) (Fig. 71). 
However, in HeLaMRP cells, there was a steady increase in the number of necrotic 
cells with Adriamycin concentration at 37°C and 42°C (Fig. 7J). 
Comparison of expression of apoptotic proteins between HeLa and 
HeLaMRP cells. Sorne studies have reported differences in the expression of 
apoptotic proteins between sensitive and drug-resistant cells. We deterrnined whether 
there were differences in endogenous levels of expression of apoptotic factors 
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between the parental and MDR HeLa cell lines. The previous figures show that 
endogenous levels of expression of Bax (Fig.2), cytochrome c (Fig. 3) and ICAD 
(Fig. 6) are very similar in HeLa and HeLa MRP cells, along with the basal activity 
of caspases 9 and 3 (Figs. 4, 5). 
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DISCUSSION 
Clinical drug resistance remains one of the primary causes of suboptimal 
outcomes in cancer therapy (Linn and Giaccone, 1995) and understanding the cause 
for this phenomenon could answer many of the questions and complexities of cancer 
treatment. It was first documented experimentally in mouse leukemic cells that 
acquired resistance to 4-amino-NlO-methyl-pteroylglutamic acid in a laboratory 
model in 1950 (Burchenal et al., 1950). The mechanisms of MDR with known 
clinical significance are the activation of transmembrane ABC transporter proteins 
such as P-gp and MRP1, which efflux a variety of chemical substances from cells, 
activation of enzymes of the glutathione detoxification system (Schroder et al, 1996) 
and alterations of genes and proteins involved in the control of apoptosis (Glisson et 
al., 1989). 
This report demonstrates the induction of apoptosis by hypertherrnia alone or 
combined with Adriamycin, in HeLa cells and in transfected HeLa cells 
overexpressing multidrug resistance associated protein. Hypertherrnia (42oC) alone 
and Adriamycin alone induced apoptosis by the mitochondrial pathway. This was the 
case in both HeLa and HeLaMRP ceUs. Induction of mitochondrial apoptosis was 
manifested by a cascade of events including the translocation of Bax to mitochondria, 
which resulted in the liberation of cytochrome cinto the cytoplasm and acti vation of 
initiator caspase 9. Caspase 9 in tum activated the effector caspase 3, which cleaved 
its substrate ICAD. Induction of apoptosis by either 420C hypertherrnia or 
Adriamycin was confirmed morphologically by the condensation of nuclear 
chromatin, which is a later event in the apoptotic cascade. 
Higher concentrations of Adriamycin were required to induce apoptosis in 
HeLaMRP ceUs, gi ven that these ceUs are drug resistant compared to the parental 
HeLa ceUs. A concentration of 2 ,uM Adriamycin induced lower levels of apoptosis in 
HeLaMRP cells than HeLa ceUs. MRPI-overexpressing HeLa cells were resistant to 
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Adriamycin-induced apoptosis at the level of ail molecular events in the 
mitochondrial pathway including translocation of Bax and cytochrome c, activation 
of caspases, cleavage of ICAD and nuclear chromatin condensation. These findings 
are in agreement with previous work which showed that HeLaMRP cells exhibit 
resistance to cytotoxicity induced by Adriamycin, actinomycin D, etoposide and 
vincristine (Kast and Gros, 1998). We found that Adriamycin accumulation was 
lower in HeLa-MRP cells, which is likely explained by increased drug efflux by 
MRP1 in HeLaMRP cells. MDR cell lines often show decreased net accumulation of 
Adriamycin associated with energy-dependent outward efflux of cytotoxic agents 
(Inaba et al., 1979). Certain studies have reported that MRP1-overexpressing cells 
show increased drug efflux compared to the drug sensitive counterparts (Bakker et 
al., 1997). 
In general, hyperthermia caused a similar extent of apoptosis in both drug 
sensitive and MDR HeLa cells. This was the case for ail of the molecular events in 
the apoptotic cascade, from Bax translocation, caspase activation and cleavage of 
caspase substrates. This finding has important significance for the clinical application 
of hyperthermia in tumors containing drug resistant cells. Tumors often respond to 
initial treatments with chemotherapy, but subsequently do not respond to the drugs 
once resistance develops. These drug resistant tumor cells are sensitive to heat and 
could therefore be eliminated using hyperthermia (Bates and Mackillop, 1986; 
Souslova & Averill-Bates, 2004). 
In general, hyperthermia (42oC) increased the level of apoptosis caused by 
Adriamycin, compared to 37oC, in both drug sensitive and MDR cells. It was 
previously reported that Adriamycin showed strong interactions with heat and 
enhancement of drug cytotoxicity was seen at non-lethal temperatures (38 -42°C) in 
other cell types (Bates and Mackillop, 1986, 1987). This study shows that 
hyperthermia increased intracellular Adriamycin accumulation in HeLa cells, but not 
in HeLaMRP cells. Heat appears to influence drug permeability to Adriamycin in 
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HeLa cells, but not in HeLaMRP cells. However, the exact mechanisms of cell death 
caused by hyperthermia and drugs are still a matter of debate. Heat would likely 
increase the generation of radicals produced by natural metabolic processes and also 
by free radical-generating drugs such as Adriamycin (Roti Roti and Laszlo, 1988). 
Adriamycin is known to generate oxidative stress with the subsequent fonnation of 
lipid peroxidation products (Gille and Nohl, 1997). Hyperthennia alone is able to 
cause oxidative stress by generation of reactive oxygen species (ROS) in cells (Lord­
Fontaine and Averill, 1999) and an imbalance in the cellular redox equilibrium by 
depletion of cellular thiols (Mitchell and Russo, 1983). Hyperthermia can also cause 
GSH depletion by increasing the level of lipid peroxides (Anderstam et aL, 1992), 
which could result in an enhancement of Adriamycin cytotoxicity due to less 
detoxification of drug. Furthermore, the rates of chemical and biochemical reactions 
increase with temperature. Thus the rates of reactions between Adriamycin and both 
intracellular and extracellular molecules, including cellular membrane components 
and the critical cellular targets, would also increase with temperature. 
HeLaMRP cells have a severe redox imbalance due to lower activity of the 
enzyme glutathione peroxidase (GPx) and lower levels of glutathione (GSH), 
compared to HeLa cells (Souslova and Averill-Bates, 2004). GPx and GSH are 
important antioxidants which protect cellular targets such as DNA, proteins and 
membrane lipids against the damaging effects of oxidative processes (Halliwell and 
Gutteridge, 1999). GSH plays an important role in detoxification of ROS, 
electrophiles and oxyanions either by reduction of conjugation (Wang, 1998). Due to 
the redox imbalance, HeLaMRP cells wouId be more vulnerable to the oxidative 
stress caused by both heat and Adriamycin, relative to HeLa cells. This could account 
for the good sensitivity of HeLaMRP cells to heat and Adriamycin, despite the lack 
of heat-induced drug accumulation. This idea can be supported by several studies on 
the influence of the GSH redox pathway on cellular sensitivity to Adriamycin. It was 
shown that human ovarian cancer lines (Hamilton et aL, 1985), MCF-7 breast tumour 
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cells (Dusre et al., 1989) and HL-60 leukemic cells (Raghu et al., 1993) were 
sensitized to Adriamycin through depletion of GSH. 
The mechanisms of induction of apoptosis by toxic compounds such as 
Adriamycin are often dependent on different cell types. In support of our findings, 
several studies confirmed the ability of Adriamycin to trigger apoptosis by the 
mitochondria mediated pathway. Adriamycin was shown to induce apoptosis by 
favouring cytochrome c release and consequent formation of the apoptosome 
complex in cardiac cells. This occurred through up-regulation of Bax, which induces 
cytochrome c release by facilitating mitochondrial pore opening (Wang et al., 
1998a,b), or by down-regulation of Bel-XL, which is a member of the Bcl-2 protein 
family that blocks cytochrome c release (Kim et al., 2003). One study revealed that 
Adriamycin induced apoptosis in ATC cells by altering the acetylation state of 
histone. Adriamycin reduced histone deacetylase activity and induced 
hyperacetylation of histone 3, which leads to cell death (Rho et al., 2005). Another 
study suggests that subtoxic concentrations of Adriamycin can enhance TRAIL­
induced apoptosis via depletion of antiapoptotic protein in the human prostate cancer 
cell line LNCaP (Kang et al., 2005). Recently, Eom and coworkers showed that 
different doses of Adriamycin activated different regulatory mechanisms to induce 
either apoptosis or cell death through mitotic catastrophe. For instance, high dose 
Adriamycin-induced apoptosis, but not low dose adriamycin-induced mitotic 
catastrophe, led to transient activation of NF-kappaB and strong, sustained activations 
of p38, c-Jun N-terminal kinase and caspases (Eom et al., 2005). 
The development of strategies to overcome MDR has received considerable 
interest. Increased drug accumulation and drug resistance reversaI with P-gp 
inhibitors have been weil documented in vitro, but only suggested in elinical trials. 
Clinical trials on the design of early resistance reversaI have shown statistically 
significant benefits with the use of P-gp inhibitors in combination with 
chemotherapy. Recent advances in medicine and science have provided multiple 
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agents for use in the struggle against MDR. Presently there are many improved 
chemotherapy drug and targeted therapies that act at a number of sites and by a 
variety of mechanisms to Iimit cancer cell proliferation. Conventional methods that 
are used to overcome MDR often involve the coadministration of chemosensitizers 
and anticancer drugs. Preclinical studies have described the raie of hyperthermia as a 
technique to increase the activity of chemotherapeutic agents (Gerco et al., 1987). 
Combined with chemotherapeutic drugs, hyperthermia appears to be a useful strategy 
to combat the MDR phenotype mediated by both P-gp and MRPI (Souslova and 
Averill-Bates, 2004; Larrivee and Averill, 1999; Bates and Mackillop, 1990). 
Van der Zee and coworkers investigated the combined effect of hyperthermia 
on radiotherapy in advanced tumors of the bladder, cervix and rectum. They obtained 
a complete-response rate of 55%, which was expected to be only 39% without 
hyperthermia. The addition of hyperthermia seemed to be most important for cervical 
cancer, for which the complete-response rate was 83%, compared with 57% after 
radiotherapy alone. Furthermore, 3-year overall survival was 27% with radiotherapy 
alone, which increased up to 51 % when it was combined with hyperthermia (Van der 
Zee et al., 2000). Literature reviews regarding response rates of addition of 
hyperthermia to radiotherapy in tumors of breast cancer, malignant melanoma and 
neck nodes suggest a clinical thermal enhancement ration of 1.5 to 1.7 (Review: Van 
der Zee, 2002). 
Hyperthermia combined with chemotherapy also reveals promising results. 
For instance, simultaneous combination of cisplatin and hyperthermia in recurring 
cervical cancer, following irradiation, resulted in a 50% response rate, which was 
expected to be 15% without hyperthermia (De Wit et al., 1999). Several phase 1 and 
phase II clinical studies using combinations of hyperthermia and drug treatment have 
reported good response rates for treatment of limb melanoma (Engelhardt, 1987), 
pel vic tumors (Rietbrock et al., 1997), intra-peritoneal metastases (Alexander and 
Fraker, 1996) and other refractory tumors (Wiedemann et al., 1997). Severa! phase II 
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studies on hyperthermia in combination with pre- and/or postoperative chemotherapy 
in high-risk sarcomas have demonstrated quite impressive 5-year overall survival 
rates (lssels et al., 2001). 
In conclusion, this study demonstrates that hyperthennia could be useful as a 
modifier of multidrug resistance involving MRPI. An important finding is that MDR 
cells overexpressing MRPI do not exhibit cross resistance to heat. Adriamycin can 
cause cell death by the mitochondrial pathway of apoptosis involving cytochrome c 
release from mitochondria and the activation of caspases. Regional hyperthermia 
combined with Adriamycin could be a useful strategy for the elimination of tumours 
containing drug resistant cells via a targeted approach at the clinicallevel. 
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Figure 2.1: Adriamycin accumulation in HeLa and HeLaMRP cells: effect of 42°C 
hyperthermia. HeLa (A-D) and HeLaMRP cells (E-H) were incubated with lOflM (A, 
B, E and F) and 20flM (C, D, Gand H) Adriamycin for 60 min in DMEM containing 
10% FBS, at 3rC (A, C, E and G) or 42°C (B, D, F and H). Magnification x400. 
Quantification of images (1) was obtained for both cell lines, representing the relative 
fluorescence (average grey values). Values for fluorescence are expressed relative to Hela 
cells treated at 3rC with lOflM of Adriamycin, which was designated as 1. Means ± 
SEM are shown from at least three different experiments. Significant difference between 
HeLa and HeLa MRP cells: a. lOflM drug; b. 20flM drug, p<O.OS (*). 
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Figure 2.2: Induction of translocation of Bax from the cytoplasm to mitochondria by 
Adriamycin alone or combined with 42°C hyperthermia. HeLa (2A, 2E) and 
HeLaMRP cells (2B, 2F) were treated with different concentrations of Adriamycin (0­
2jlM for HeLa and O-lOjlM for HeLaMRP) at 3re for l5h or for lh at 42°e and 
subsequently l4h at 3re. Bax (2lkDa) levels in cytoplasmic (2A, 2B) and mitochondrial 
fractions (2E, 2F) were analysed by immunoblotting. Protein levels were quantified by 
densitometry in HeLa (2e, 20) and HeLaMRP (2D, 2H) cells. Bax levels were expressed 
relative to untreated HeLa cells at 37°C, designated as 1. Means ± SEM are shown from 
at least four independent experiments. a, significantly different from corresponding 
control (no drug) at 3rc. b, significantly different from corresponding treatment (no 
drug) at 42°C. c, significantly different at 42°e from corresponding conditions at 3re, 
p<0.05(*) and p<O.OOl (**). 
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Figure 2.3: Induction cytochrome c release from mitochondria into the cytoplasm by 
Adriamycin alone or combined with 42°C hyperthermia. HeLa (3A, 3E) and 
HeLaMRP ceUs (3B, 3F) were treated with different concentration of Adriamycin (0­
2p,M for HeLa, O-lOp,M for HeLaMRP) at 37°C for l5h or lh at 42°C and l4h at 37°C. 
Following immunoblotting, prateins levels were quantified by densitometry in HeLa (3C, 
40) and HeLaMRP (3D, 3H) cells. Cytochrame c (l6kDa) levels were expressed relative 
to untreated HeLa ceUs at 37°C, designated as 1. Means ± SEM are shown from at least 
four independent experiments. a, significantly different fram cOITesponding contrai (no 
drug) at 37°C. b, significantly different from cOlTesponding treatment (no drug) at 42°C. 
c, significantly different at 42°C fram cOITesponding conditions at 37°C, p<O.05(*). 
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Figure 2.4: Activation of caspase 9 by hyperthermia and/or Adriamycin. (A) For heat 
alone, HeLa (0) and HeLaMRP cells (.) were heated (37 to 45°C) for 1h. For drug alone 
or drug combined with heat treatment, cells were incubated in monolayer with different 
concentrations of Adriamycin (O-lOILM) for l5h at 37°C or lh at 42°C + l4h at 37°C, (B) 
for HeLa and (C) HeLaMRP. Activities of caspase-9 were expressed relative to untreated 
HeLa cells at 37°C, designated as 1.0. Means ± SEM are shown from at least five 
independent experiments. a, significantly different from corresponding control (no drug) 
at 37°C. b, significantly different from corresponding treatment (no drug) at 42°C, 
p<0.05(*) and p<O.OOl (**). 
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Figure 2.5: Activation of caspase 3 by hyperthermia and/or Adriamycin. (A) For the 
effect of heat alone, HeLa (D) and HeLaMRP cells (.) were heated (37 to 45°C) for 2h 
using temperature controlled water baths (±0.02°C). For drug alone or drug combined 
with heat treatment, cells were incubated in monolayer with different concentrations of 
Adriamycin (0 to lOp,M) for l8h at 3rC or for lh at 42°C + l7h at 3rC, (B) for HeLa 
and (C) HeLaMRP cells. Activities of caspase-3 were expressed relative to untreated 
HeLa cells at 3rC, designated as 1.0. Means ± SEM are shown from at least five 
independent experiments. a, significantly different from corresponding control (no drug) 
at 37°C. b, significantly different from corresponding treatment (no drug) at 42°C, 
p<0.05(*) and p<O.OOl (**). 
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Figure 2.6: Induction of ICAD cleavage by Adriamycin and/or hyperthermia. HeLa 
(A) and HeLaMRP (B) cells were treated with Adriamycin for 18h at 37°C or for 1h at 
42°C and 17 h at 37°C. Protein levels were detected by immunoblotting and quantified by 
densitometry in HeLa (C) and HeLaMRP cells (D) and expressed relative to untreated 
HeLa cells at 37°C, designated as 1. Means ± SEM are shown from at least four 
independent experiments. a, significantly different from corresponding control (no drug) 
at 37°C. c, significantly different at 42°C from corresponding conditions at 37°C, 
p<O.05(*). 
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Figure 2.7(A-H)
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Figure 2.7: Induction of apoptosis by Adriamycin alone or combined with 
hyperthermia in HeLaMRP and HeLa cells. Cells were incubated with Adriamycin (0 
to 2p,M for HeLa, 0 to lOp,M for HeLaMRP), either alone at 37°C for l8h or combined 
with lh of 42°C hyperthermia for the first hour of drug treatment. (A) HeLa ceUs were 
incubated for l8h at 37°C or (B) for lh at 42°C and then for 17h at 37°C, without drug 
treatment. HeLa ceUs were incubated with (C) 2p,M Adriamycin at 37°C for l8h, or (D) 
with 2p,M Adriamycin for lh at 42°C and then for 17h at 37°C. (E) HeLaMRP cells were 
incubated for l8h at 37°C or (F) for 1h at 42°C and then for 17h at 37°C, without drug 
treatment. (0) HeLaMRP ceUs were incubated with a lOp,M Adriamycin at 37°C for l8h, 
or (H) with lOp,M Adriamycin for lh at 42°C and then 17h at 37°C. Magnification: 320X. 
Quantification of images for (1) HeLa and (1) HeLaMRP ceUs, represents the percentage of 
apoptotic or necrotic ceUs, relative to total ceUs. Means ± SEM shown are from at least 
four different experiments. a, induction of apoptosis by Adriamycin relative to untreated 
control at 37°C. b, induction of necrosis by Adriamycin relative to corresponding control at 
37°C, p<O.OS(*) and p<O.OOl (**). Comparison of curves: For necrosis at 37 versus 42°C 
in HeLa cells; p<O.OOl. For apoptosis in HeLa versus HeLa~!IRP ceUs at 37°C, p<O.OS. 
CHAPTERIII 
Conclusion 
Chemotherapy is among the classical treatments of cancer. However, 
development of MDR by tumour ceUs is a major obstacle in the successful use of 
chemotherapy (Linn and Giaccone, 1995). For instance, fifty percent of human 
cancers are either totally resistant to chemotherapy or respond only transiently, after 
which they are no longer affected by commonly used anticancer drugs. Improved 
understanding of MDR could answer many of the questions and complexities of 
cancer treatment. Presently there are many strategies in use at the clinical level to 
combat MDR, although with limited success. 
Coadministration of chemosensitizers and anticancer drugs is currently used 
as a method to overcome MDR. Verapamil, quinine and cyclosporine A are among 
the first generation of chemosensitizers that can reverse the MDR phenotype by 
reducing drug efflux from P-gp expressing ceUs (Georges et al, 1990). Several 
randomized clinical trials have shown benefits with these chemosensitizers. However, 
their clinical use is often limited due to their toxicity. Second generation agents such 
as valspodar and biricodar show better impact but were confounded by unpredictable 
pharrnacokinetic interactions and interactions with other transporter proteins. Third 
generation P-gp inhibitors such as XR9576, LY335979, RlO1933 and üNT-093 have 
shown high effectiveness and specificity for P-gp in clinical trials. The continued 
development of these agents may establish the true therapeutic potential of P-gp­
mediated MDR reversai (Thomas and Coley, 2003). To date, reversai of MRPI 
mediated drug resistance has received little attention at the clinicallevel. 
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Hyperthennia is a recent type of cancer treatment in which body tissue is 
exposed to temperatures which are several degrees above body temperature (up to 
45°C). The extensive amount of biological in vitro and in vivo experimental research 
on hyperthennia during the last two decades has established it to be a valuable new 
tool in cancer therapy (Liu and Wilson, 1998). Hyperthermia, usually with nominal 
injury to normal tissues, can damage and kill cancer cells by damaging proteins 
within the cells leading to the shrinkage of tumours (van der Zee, 2002; Hildebrandt 
et al., 2002). This fact has been supported by the work of Fajardo, who proved that 
most nonnal tissues are undamaged by treatment for 1h at temperatures of up to 44°C 
(Fajardo, 1984). Several studies using hyperthennia at the clinical level have 
demonstrated complete overall response rates of 13% (Hetzel et al., 1987). 
For hyperthennia in combination therapy, a large amount of medical evidence 
demonstrates remarkable improvement in response rates when it is used combined 
with radiation therapy and chemotherapy (Wust et al., 2002). Several phase 1 and II 
clinical studies have used combinations of hyperthennia and drug treatment. These 
studies have reported good responses for treatment of limb melanoma (Fraker, 2004), 
pelvic tumors (Hildebrandt et al., 2004; Rietbrock et al., 1997), intra-peritoneal 
metastases (Alexander and Fraker, 1996) and other refractory tumors (Wiedeman et 
al., 1997). Several phase II studies on hyperthermia in combination with pre- and/or 
postoperative chemotherapy in high-risk sarcomas have demonstrated quite 
impressive 5-year overall survival rates (Issels et al., 2001; Wendtner et al., 2001). 
Hyperthermia combined with cisplatin chemotherapy also reveals promising results, 
particularly in recurring cervical cancer, following irradiation (De Wit et al., 1999; 
Rietbroek et al, 1997). Van der Zee and coworkers found promising results for the 
added effect of hyperthermia on radiotherapy in advanced tumors of the bladder, 
cervix and rectum (Van der Zee et al., 2000). Literature reviews regarding respond 
rates of addition of hyperthennia to radiotherapy in tumor of breast cancer, malignant 
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melanoma and neck nodes suggest a clinical thermal enhancement ration of 1.5 to 1.7 
(Review: Van der Zee, 2002). 
Our previous studies at the cellular level demonstrated that hyperthermia 
combined with chemotherapy and chemosensitizers could be a useful strategy to 
combat the multidrug resistance phenotype mediated by P-gp (Turcotte and Averill­
Bates, 2001; Larrivée and Averill, 2000, 1999; Averill and Su, 1999; Averill and 
Larrivée, 1998; Bates and Mackillop, 1990). Our findings demonstrated that over 
expression of P-gp can be modulated by hyperthermia combined with melphalan and 
ethacryinc acid, verapamil and cyclosporine A (Turcotte and Averill-Bates, 2001; 
Averill and Larrivée, 1998; Larrivée and Averill, 2000). When hyperthermia was 
used in combination with cyclosporine A in multidrug resistant CHRC5 Chinese 
hamster ovary cells, this caused an increase in melphalan uptake and a decrease in 
melphalan efflux out of MDR cells, leading to an overall increase in intracellular drug 
accumulation. The combined effect of hyperthermia and verapamil increases 
intracellular accumulation of drugs such as Adriamycin in certain muJtidrug-resistant 
cell lines. This combination alters membrane perrneability to Adriamycin and 
consequently enhances the cytotoxicity of the drug. 
Recent data showed that hypertherrnia administered with appropriate 
scheduling with drug caused a modest increase in etoposide-induced apoptosis in 
both the drug sensitive parental cell line (e.g. HeLa) and multidrug resistant (e.g. 
Hela-MRP) cells (Souslova and Averill-Bates, 2004). Cytotoxicity measurements 
showed that folated liposomes combined with hypertherrnia were found to be over 3­
fold more effective than the free drug (Adriamycin) for growth inhibition of human 
cervical carcinoma derived KB31 cells (Gaber, 2002). In an effort to overcome 
chemoresistance of human malignant glioma cells, Hermisson and Weiler (2000) 
analyzed the modulation of drug-induced ceH death by hypertherrnia in 4 human 
malignant glioma cells lines, LN-18, LN-229, T98G and U87MG. The results of this 
study showed that hyperthermia might be a useful approach to overcome 
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chemoresistance of these cell lines. Although hyperthennia does not reverse 
resistance in MRP1-HeLa ceUs, we were able to induce apoptosis independently of 
the susceptibility of the cell line or treatment, and therefore hyperthermia renders 
resistant cells a bit more susceptible to the drug. However, the magnitude of cell 
death in MRP1-HeLa cells is still much lower than for drug sensitive cells (and 
higher drug concentrations are still required). 
The findings of the present study show that Adriamycin activated the 
mitochondrial pathway in HeLa cells and that 42°C hyperthennia caused an increase 
in Adriamycin induced apoptosis. This study also evaluated the effect of 
hyperthermia combined with Adriamycin on the induction of apoptosis in MDR ceUs 
with overexpression of MRPl. In this study, we used higher concentrations of 
Adriamycin for induction of apoptosis in HeLa-MRP ceUs, which can be explained 
by the fact that these ceUs are resistant to cytotoxicity induced by Adriamycin, 
compared to the parental ceUs. This is in agreement with findings that HeLaMRP 
ceUs exhibit resistance to actinomycin D, etoposide, vincristine and Adriamycin 
induced cytotoxicity (Kast and Gros, 1998). Adriamycin-induced apoptotic ceU death 
was accompanied by caspase-9 and caspase-3 activation, as weil as the cleavage of 
the caspase-3 substrate ICAD, which was preceded by mitochondrial cytochrome c 
release. These results suggest that the release of mitochondrial cytochrome c and the 
sequential activations of caspase-9 and caspase-3 are important events in the signal 
transduction pathway of Adriamycin-induced apoptotic cell death in both HeLa and 
HeLaMRP cells. 
We found that hyperthermia alone was equally effective in inducing apoptosis 
in HeLa and HeLaMRP ceUs. This finding is extremely important since the MDR 
ceUs are sensitive to heat kiUing. Therefore, hypelthermia could be and effective 
strategy for eliminating MDR cells (Bates and Mackillop, 1986). The effect of 
hyperthermia was investigated by Zang and coworkers, in MDR mediated by P-gp in 
K562/ADM and Tca8113 cell lines. The result of this study was that 41°C 
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hyperthennia reduced MDR1 and MRP expression and enhanced intracellular drug 
concentration (Zang et al., 2003). There are several possible explanations for that, 
such as Adriamycin is known to generate oxidative stress with subsequent fonnation 
of lipid peroxidation products (Gille and Nohl, 1997; Ollinger and Brunmark, 1994). 
Hyperthermia alone is able to cause oxidative stress by generation of ROS in cells 
(Lord-Fontaine and Averili, 1999; Flanagan, 1998; Lin, 1991) and an imbalance in 
the cellular redox equilibrium by depletion of cellular thiols (Mitchell and Russo, 
1983). GPx and GSH are enzymes which pratects the membrane lipids against 
oxidation (Halliwell and Gutteridge, 1999). To exacerbate the redox imbalance, 
activity of the antioxidant enzyme GPx was also lower and additionally level of 
glutathione (GSH) was depleted in HeLaJVIRP cells (Souslova and Averill-Bates, 
2004). GSH is a critical factor in MRP1-mediated drug resistance (Versantvoort et 
al., 1995; Zaman et al., 1995). It plays an important raie in detoxification of ROS, 
electrophiles and oxyanions either by reduction or conjugation (Wang, 1998; Meister, 
1994; Meister and Anderson, 1983). Hyperthennia possibly caused more depletion of 
GSH in HeLaMRP cells, therefore it would be more vulnerable to the oxidative stress 
caused by Adriamycin. This finding can be supported by several studies on the 
influence of GSH redox pathway on cel! sensitivity to Adriamycin have shown that 
human ovarian cancer lines (Hamilton et al., 1985), MCF-7 breast tumour cells 
(Dusre et al., 1989) and HL-60 leukemic cel!s (Raghu et al., 1993) were sensitized ta 
Adriamycin through depletion of GSH. 
In conclusion, this study demonstrates clearly that hyperthennia could be 
useful as a modifier of multidrug resistance mediated by MRPl. Adriamycin can 
cause cell death by the mitochondrial pathway of apoptosis involving cytochrame c 
release from the mitochondria and the activation of caspases in human cervical 
adenocarcinoma cells (HeLa and HeLaMRP). Based on cellular studies, hyperthermia 
combined with Adriamycin could be a useful strategy for elimination of tumour cells 
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at the clinical level. However further investigation of mechanisms of toxicity induced 
by heat and drugs are required. 
Future perspectives 
We have found that Adriamycin can cause cell death by the mitochondrial 
pathway of apoptosis involving cytochrome c release from the mitochondria and the 
activation of caspases. However, the possible involvement of the death receptor 
pathway of apoptosis should also be taken into account. Future perspectives of our 
study will be the investigation of the role of death receptors in Adriamycin-induced 
apoptosis. Apoptosis could also occur via death receptor pathways without the 
involvement of cytochrome c. With respect to the death receptor-mediated pathway, 
Adriamycin was shown to increase apoptosis by recombinant Fas ligand (rFsaL) in 
neonatal rat cardiomyocytes (Yomaoka et al., 2000). 
To determine the involvement of death receptor mediated cell death by 
Adriamycin alone and combined with hypelthermia in HeLa and HeLaMRP cells, the 
activity of initiator caspase-S was measured. Hyperthermia induced the activation of 
caspase-S (Fig. lA) relative to unheated control cells at 37°C. Activation of caspase S 
was observed at temperatures of 41-45°C in HeLa and HeLaMRP cells (Fig lA). 
HeLaMRP cells were slightly less sensitive to heat (Fig. lA). Adriamycin (0-2fA.M for 
HeLa, O-IOfA.M for HeLaMRP cells) increased caspase-S activity in HeLa cells but 
caspase-S activity was decreased by Adriamycin in HeLaMRP cells (Fig. lB, C). 
Hyperthermia was unable to increase caspase-S activation by Adriamycin in 
HeLaMRP cells. Future studies will determine the reasons for differing responses of 
caspase-S in Adriamycin treated HeLa and HeLa MRP cells. 
95 
The MRP-transfected HeLa cells display an increase in resistance to 
Adriamycin that is proportional to the levels of integral membrane MRP expression. 
Overexpression of the human MRP protein causes a forro of multidrug resistance 
similar to that conferred by P-glycoprotein, although the two proteins are only 
distantly related. In contrast to P-glycoprotein, human MRP has also been shown to 
be a primary active transporter of a structurally diverse range of organic anionic 
conjugates, sorne of which may be physiological substrates. Consequently, the use of 
higher concentrations of Adriamycin may lead to the induction of apoptosis. 
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Figure3.!: Activation of caspase 8 by hyperthermia and/or Adriamycin. (A) HeLa 
([J) and HeLaMRP cel1s (.) were heated (37 to 45°C) for 2h. HeLa (B) and HeLaMRP 
(C) ceUs were incubated in monolayer with different concentrations of Adriamycin for 
l8h at 37°C or for lh at 42°C and l4h at 37°C. Activities of caspase-8 were expressed 
relative to untreated HeLa ceUs at 37°C, designated as 1.0. Means ± SEM are shown from 
at least three independent experiments. 
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